[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fbJRY3x9JqYfRsOOW8f2i4FboGqxCx8zmUxTzC09CdzE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"Rutgers, The State University of New Jersey",[4],483,false,142,20,159396,65,324,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Breast Cancer",15,{"name":18,"count":19},"Prostate Cancer",13,{"name":21,"count":22},"Autism Spectrum Disorder",10,{"name":24,"count":25},"Depression",9,{"name":27,"count":28},"Opioid Use",8,{"name":30,"count":28},"Parkinson Disease",{"name":32,"count":28},"Anxiety",{"name":34,"count":35},"Obesity",7,[37,42,47,52,57,62,67,72,77,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT02315196","Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer","2021-02-08","pegylated liposomal doxorubicin hydrochloride",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT04452344","Opioid Analgesic Reduction Study","2023-07-07","opioid-containing analgesic",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04294264","TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer","2024-03-27","Oxaliplatin",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT03428802","Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability","2024-11-24","Pembrolizumab",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT02677051","Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism","2025-12","Sulforaphane",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05411744","One-month Latent Tuberculosis Treatment for Renal Transplant Candidates","2026-01-16","1 month Rifapentine, Isoniazid and Vitamin B6",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT05703425","The Effect of Sulfasalazine on CRH Levels in Pregnant Women","2026-01-31","Sulfasalazine",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT06658574","Oral Acetaminophen for Post-Op Pain Management in Bariatric Surgery Patients","2026-02","Acetaminophen",{"nctId":78,"briefTitle":79,"date":75,"intervention":80},"NCT04880707","Twin Block, Pain Medications and Third Molar Extractions","Twin block local anesthetic nerve block using standard dental anesthetic",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT05806931","Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer","2026-05-01","TAS-102, oxaliplatin, irinotecan with bevacizumab",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,127,145,173,191,219,237,255,280,307,329,347,376,394,420,438,553,676,712,748,784,820,847,878,899,926,944,971,999,1017,1041,1065,1095,1113,1131,1149,1167,1185,1211,1231,1258,1276,1294,1312,1330,1348,1366,1391,1416,1442,1466,1486,1509,1534,1561,1579,1605,1630,1654,1712,1735,1763,1781,1799,1827,1845,1880,1909,1934,1952,1977,2002,2035,2053,2079,2097,2122,2146,2175,2193,2217,2244,2269,2298,2316,2341,2368,2407,2432,2456,2479,2506,2532,2550,2578,2596,2626,2644,2668,2694,2769,2814,2869,2931,2957,2989,3011,3042,3093,3115,3144,3162,3185,3203,3221,3239,3257,3281,3304,3329,3347,3371,3396,3421,3439,3463,3481,3499,3517,3535,3553,3579,3597,3621,3639,3661,3685,3703,3721,3739,3757,3775,3793,3811,3829,3847,3865,3891,3918,3944,3962,3983,4008,4026,4049,4067,4085,4103,4121,4139,4157,4175,4220,4254,4278,4304,4322,4340,4358,4376,4401,4419,4446,4464,4488,4506,4532,4557,4575,4602,4620,4642,4660,4685,4709,4731,4769,4794,4839,4871,4898,4926,4956,5005,5033,5058,5083,5106,5124,5142,5167,5185,5209,5232,5255,5273,5291,5309],{"intervention":95,"totalTrials":96,"cells":97},"Fluorouracil",1,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":125},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":96,"soonestReadout":114},[109],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":123},"NCT07158164","DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment","RECRUITING",[91],"2027-07-07","2029-07-07","2025-08-27",100,[119,120,121,122],"Colorectal Neoplasms","Breast Neoplasms","Head and Neck Neoplasms","Gastro-Intestinal Intraepithelial Neoplasia",[95,124],"Xeloda",{"trials":126,"activeCount":100},[],{"intervention":124,"totalTrials":96,"cells":128},{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":137,"NA":143},{"trials":130,"activeCount":100},[],{"trials":132,"activeCount":100},[],{"trials":134,"activeCount":100},[],{"trials":136,"activeCount":100},[],{"trials":138,"activeCount":96,"soonestReadout":114},[139],{"nctId":110,"briefTitle":111,"status":112,"phases":140,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":141,"interventions":142},[91],[119,120,121,122],[95,124],{"trials":144,"activeCount":100},[],{"intervention":146,"totalTrials":96,"cells":147},"CeFAZolin 1000 MG",{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":171},{"trials":149,"activeCount":100},[],{"trials":151,"activeCount":100},[],{"trials":153,"activeCount":100},[],{"trials":155,"activeCount":100},[],{"trials":157,"activeCount":96,"soonestReadout":163},[158],{"nctId":159,"briefTitle":160,"status":161,"phases":162,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":169},"NCT07549542","Efficacy and Safety of Intraosseous Antibiotic Prophylaxis in Total Hip Replacement","ENROLLING_BY_INVITATION",[91],"2026-10","2026-11","2025-10-20",25,[168],"Antibiotic Prophylaxis Surgery",[146,170],"Saline",{"trials":172,"activeCount":100},[],{"intervention":170,"totalTrials":96,"cells":174},{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":189},{"trials":176,"activeCount":100},[],{"trials":178,"activeCount":100},[],{"trials":180,"activeCount":100},[],{"trials":182,"activeCount":100},[],{"trials":184,"activeCount":96,"soonestReadout":163},[185],{"nctId":159,"briefTitle":160,"status":161,"phases":186,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":187,"interventions":188},[91],[168],[146,170],{"trials":190,"activeCount":100},[],{"intervention":192,"totalTrials":96,"cells":193},"Bupivacaine 0.5% Injectable Solution",{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":200,"PHASE4":202,"NA":217},{"trials":195,"activeCount":100},[],{"trials":197,"activeCount":100},[],{"trials":199,"activeCount":100},[],{"trials":201,"activeCount":100},[],{"trials":203,"activeCount":96,"soonestReadout":208},[204],{"nctId":205,"briefTitle":206,"status":112,"phases":207,"primaryCompletion":208,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":214},"NCT07349810","Post Operative Infusion Pump Pain Study",[91],"2026-06-30","2026-12-31","2026-01-01",80,[213],"Post Operative Pain",[192,215,216],"Ropivacaine 0.2% Injectable Solution","1.3% liposomal bupivacaine",{"trials":218,"activeCount":100},[],{"intervention":215,"totalTrials":96,"cells":220},{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":227,"PHASE4":229,"NA":235},{"trials":222,"activeCount":100},[],{"trials":224,"activeCount":100},[],{"trials":226,"activeCount":100},[],{"trials":228,"activeCount":100},[],{"trials":230,"activeCount":96,"soonestReadout":208},[231],{"nctId":205,"briefTitle":206,"status":112,"phases":232,"primaryCompletion":208,"completion":209,"start":210,"enrollment":211,"conditions":233,"interventions":234},[91],[213],[192,215,216],{"trials":236,"activeCount":100},[],{"intervention":216,"totalTrials":96,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":247,"NA":253},{"trials":240,"activeCount":100},[],{"trials":242,"activeCount":100},[],{"trials":244,"activeCount":100},[],{"trials":246,"activeCount":100},[],{"trials":248,"activeCount":96,"soonestReadout":208},[249],{"nctId":205,"briefTitle":206,"status":112,"phases":250,"primaryCompletion":208,"completion":209,"start":210,"enrollment":211,"conditions":251,"interventions":252},[91],[213],[192,215,216],{"trials":254,"activeCount":100},[],{"intervention":66,"totalTrials":96,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":263,"PHASE4":265,"NA":278},{"trials":258,"activeCount":100},[],{"trials":260,"activeCount":100},[],{"trials":262,"activeCount":100},[],{"trials":264,"activeCount":100},[],{"trials":266,"activeCount":96,"soonestReadout":65},[267],{"nctId":63,"briefTitle":64,"status":268,"phases":269,"primaryCompletion":65,"completion":270,"start":271,"enrollment":166,"conditions":272,"interventions":277},"ACTIVE_NOT_RECRUITING",[91],"2029-06-30","2022-07-01",[273,274,275,276],"Latent Tuberculosis","End Stage Renal Disease","Renal Transplant Candidate for Right Kidney","Renal Transplant Candidate for Left Kidney",[66],{"trials":279,"activeCount":100},[],{"intervention":281,"totalTrials":96,"cells":282},"Melatonin",{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":287,"PHASE3":289,"PHASE4":303,"NA":305},{"trials":284,"activeCount":100},[],{"trials":286,"activeCount":100},[],{"trials":288,"activeCount":100},[],{"trials":290,"activeCount":96,"soonestReadout":295},[291],{"nctId":292,"briefTitle":293,"status":112,"phases":294,"primaryCompletion":295,"completion":296,"start":297,"enrollment":298,"conditions":299,"interventions":302},"NCT05084196","Melatonin for Prevention of Kidney Injury",[90],"2027-06-01","2027-12-31","2023-06-05",300,[300,301],"Acute Kidney Injury","Adverse Drug Event",[281],{"trials":304,"activeCount":100},[],{"trials":306,"activeCount":100},[],{"intervention":46,"totalTrials":96,"cells":308},{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":325,"NA":327},{"trials":310,"activeCount":100},[],{"trials":312,"activeCount":100},[],{"trials":314,"activeCount":100},[],{"trials":316,"activeCount":96,"soonestReadout":45},[317],{"nctId":43,"briefTitle":44,"status":268,"phases":318,"primaryCompletion":45,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":323},[90],"2026-07-31","2021-01-04",1815,[27],[46,324],"two over-the-counter analgesics",{"trials":326,"activeCount":100},[],{"trials":328,"activeCount":100},[],{"intervention":324,"totalTrials":96,"cells":330},{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":335,"PHASE3":337,"PHASE4":343,"NA":345},{"trials":332,"activeCount":100},[],{"trials":334,"activeCount":100},[],{"trials":336,"activeCount":100},[],{"trials":338,"activeCount":96,"soonestReadout":45},[339],{"nctId":43,"briefTitle":44,"status":268,"phases":340,"primaryCompletion":45,"completion":319,"start":320,"enrollment":321,"conditions":341,"interventions":342},[90],[27],[46,324],{"trials":344,"activeCount":100},[],{"trials":346,"activeCount":100},[],{"intervention":348,"totalTrials":96,"cells":349},"bupivacaine liposome injectable suspension",{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":356,"PHASE4":372,"NA":374},{"trials":351,"activeCount":100},[],{"trials":353,"activeCount":100},[],{"trials":355,"activeCount":100},[],{"trials":357,"activeCount":96,"soonestReadout":362},[358],{"nctId":359,"briefTitle":360,"status":161,"phases":361,"primaryCompletion":362,"completion":363,"start":364,"enrollment":365,"conditions":366,"interventions":370},"NCT06077422","Exparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain",[89,90],"2027-01-11","2027-04-05","2024-01-11",150,[367,27,368,369],"Pain, Postoperative","Perioperative Complication","Heart Diseases",[348,371],"Bupivacaine Hydrochloride",{"trials":373,"activeCount":100},[],{"trials":375,"activeCount":100},[],{"intervention":371,"totalTrials":96,"cells":377},{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":384,"PHASE4":390,"NA":392},{"trials":379,"activeCount":100},[],{"trials":381,"activeCount":100},[],{"trials":383,"activeCount":100},[],{"trials":385,"activeCount":96,"soonestReadout":362},[386],{"nctId":359,"briefTitle":360,"status":161,"phases":387,"primaryCompletion":362,"completion":363,"start":364,"enrollment":365,"conditions":388,"interventions":389},[89,90],[367,27,368,369],[348,371],{"trials":391,"activeCount":100},[],{"trials":393,"activeCount":100},[],{"intervention":395,"totalTrials":96,"cells":396},"High Dose Buprenorphine",{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":403,"PHASE4":416,"NA":418},{"trials":398,"activeCount":100},[],{"trials":400,"activeCount":100},[],{"trials":402,"activeCount":100},[],{"trials":404,"activeCount":96,"soonestReadout":409},[405],{"nctId":406,"briefTitle":407,"status":112,"phases":408,"primaryCompletion":409,"completion":209,"start":410,"enrollment":411,"conditions":412,"interventions":414},"NCT05589181","High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)",[90],"2026-09-01","2023-04-06",140,[413],"Opioid Use Disorder",[395,415],"Standard Buprenorphine Dose",{"trials":417,"activeCount":100},[],{"trials":419,"activeCount":100},[],{"intervention":415,"totalTrials":96,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":428,"PHASE4":434,"NA":436},{"trials":423,"activeCount":100},[],{"trials":425,"activeCount":100},[],{"trials":427,"activeCount":100},[],{"trials":429,"activeCount":96,"soonestReadout":409},[430],{"nctId":406,"briefTitle":407,"status":112,"phases":431,"primaryCompletion":409,"completion":209,"start":410,"enrollment":411,"conditions":432,"interventions":433},[90],[413],[395,415],{"trials":435,"activeCount":100},[],{"trials":437,"activeCount":100},[],{"intervention":439,"totalTrials":35,"cells":440},"Carboplatin",{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":473,"PHASE3":547,"PHASE4":549,"NA":551},{"trials":442,"activeCount":100},[],{"trials":444,"activeCount":100},[445,460],{"nctId":446,"briefTitle":447,"status":448,"phases":449,"primaryCompletion":450,"completion":451,"start":452,"enrollment":453,"conditions":454,"interventions":458},"NCT02621398","Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer","COMPLETED",[88],"2019-10-24","2024-02-29","2016-08-04",23,[455,456,457],"Stage II Non-Small Cell Lung Cancer","Stage IIIA Non-Small Cell Lung Cancer","Stage IIIB Non-Small Cell Lung Cancer",[439,459,56],"Paclitaxel",{"nctId":461,"briefTitle":462,"status":463,"phases":464,"primaryCompletion":465,"completion":465,"start":466,"enrollment":467,"conditions":468,"interventions":471},"NCT01407562","Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors","TERMINATED",[88],"2016-03-29","2010-09-17",34,[469,470],"Unspecified Adult Solid Tumor - Protocol Specific","Breast Cancer - Female",[472,459,439],"Pazopanib",{"trials":474,"activeCount":546,"soonestReadout":40},[475,489,502,521,534],{"nctId":476,"briefTitle":477,"status":448,"phases":478,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":486},"NCT01649947","Modulation of Autophagy in Patients With Advanced\u002FRecurrent Non-small Cell Lung Cancer - Phase II",[89],"2015-06-30","2011-12-23",32,[483,484,485],"Non-small Cell Lung Cancer","Advanced Non-small Cell Lung Cancer","Recurrent Non-small Cell Lung Cancer",[459,439,487,488],"Hydroxychloroquine","Bevacizumab",{"nctId":490,"briefTitle":491,"status":112,"phases":492,"primaryCompletion":296,"completion":493,"start":494,"enrollment":495,"conditions":496,"interventions":498},"NCT07402473","Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer",[89],"2028-06-30","2026-03-26",50,[497],"HER2-positive Early-stage Breast Cancer",[499,500,501,439],"Trastuzumab","Pertuzumab","Docetaxel",{"nctId":38,"briefTitle":39,"status":268,"phases":503,"primaryCompletion":40,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":517},[89],"2041-07","2015-02-25",62,[508,509,510,511,512,513,514,515,516],"Estrogen Receptor-negative Breast Cancer","HER2-negative Breast Cancer","Progesterone Receptor-negative Breast Cancer","Stage IIA Breast Cancer","Stage IIB Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer","Triple-negative Breast Cancer",[41,518,519,520],"epirubicin hydrochloride","carboplatin","paclitaxel",{"nctId":522,"briefTitle":523,"status":112,"phases":524,"primaryCompletion":525,"completion":526,"start":527,"enrollment":365,"conditions":528,"interventions":531},"NCT05358548","ATATcH Alternating Treatment Plans for Advanced Cancer",[89],"2027-05-01","2028-05-01","2022-04-28",[529,530],"Head and Neck Cancer","Lung Cancer",[459,532,533,439,56],"Pemetrexed","5Fluorouracil",{"nctId":535,"briefTitle":536,"status":448,"phases":537,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":544},"NCT00608972","Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer",[89],"2015-07-12","2015-09-25","2008-05-16",31,[543],"Metastatic Breast Cancer",[545,439,488],"Doxil",3,{"trials":548,"activeCount":100},[],{"trials":550,"activeCount":100},[],{"trials":552,"activeCount":100},[],{"intervention":56,"totalTrials":554,"cells":555},6,{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":605,"PHASE3":670,"PHASE4":672,"NA":674},{"trials":557,"activeCount":100},[],{"trials":559,"activeCount":100},[560,601],{"nctId":561,"briefTitle":562,"status":448,"phases":563,"primaryCompletion":564,"completion":565,"start":566,"enrollment":567,"conditions":568,"interventions":598},"NCT03229278","Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma",[88],"2022-10-20","2022-10-30","2017-10-03",14,[569,570,571,572,573,574,575,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592,593,594,595,596,597],"Lymphoma","Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Metastatic Renal Cell Cancer","Recurrent Bladder Carcinoma","Recurrent Classical Hodgkin Lymphoma","Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Lymphoma","Recurrent Malignant Solid Neoplasm","Recurrent Renal Cell Carcinoma","Stage III Bladder Cancer","Stage III Lymphoma","Stage III Non-Small Cell Lung Cancer AJCC v7","Stage III Renal Cell Cancer","Stage III Skin Melanoma","Stage IIIA Non-Small Cell Lung Cancer AJCC v7","Stage IIIA Skin Melanoma","Stage IIIB Non-Small Cell Lung Cancer AJCC v7","Stage IIIB Skin Melanoma","Stage IIIC Skin Melanoma","Stage IV Bladder Cancer","Stage IV Lymphoma","Stage IV Non-Small Cell Lung Cancer AJCC v7","Stage IV Renal Cell Cancer","Stage IV Skin Melanoma","Stage IVA Bladder Cancer","Stage IVB Bladder Cancer","Unresectable Head and Neck Squamous Cell Carcinoma","Unresectable Solid Neoplasm",[599,600,56],"Enzyme Inhibitor Therapy","Nivolumab",{"nctId":446,"briefTitle":447,"status":448,"phases":602,"primaryCompletion":450,"completion":451,"start":452,"enrollment":453,"conditions":603,"interventions":604},[88],[455,456,457],[439,459,56],{"trials":606,"activeCount":546,"soonestReadout":55},[607,620,645,649],{"nctId":608,"briefTitle":609,"status":463,"phases":610,"primaryCompletion":611,"completion":297,"start":612,"enrollment":22,"conditions":613,"interventions":618},"NCT02748564","Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma",[89],"2018-10-18","2017-03-21",[571,614,585,587,588,593,615,616,617],"Stage III Mucosal Melanoma of the Head and Neck","Stage IVA Mucosal Melanoma of the Head and Neck","Stage IVB Mucosal Melanoma of the Head and Neck","Stage IVC Mucosal Melanoma of the Head and Neck",[619,56],"Aldesleukin",{"nctId":53,"briefTitle":54,"status":268,"phases":621,"primaryCompletion":55,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":644},[89],"2027-09-21","2018-03-08",21,[626,627,628,570,629,630,577,631,632,633,634,635,636,637,638,639,640,641,642,643],"BRCA1 Gene Mutation","BRCA2 Gene Mutation","Locally Advanced Solid Neoplasm","POLD1 Gene Mutation","POLE Gene Mutation","Recurrent Ovarian Carcinoma","Stage III Breast Cancer AJCC v7","Stage III Ovarian Cancer AJCC v8","Stage IIIA Breast Cancer AJCC v7","Stage IIIA Ovarian Cancer AJCC v8","Stage IIIB Breast Cancer AJCC v7","Stage IIIB Ovarian Cancer AJCC v8","Stage IIIC Breast Cancer AJCC v7","Stage IIIC Ovarian Cancer AJCC v8","Stage IV Breast Cancer AJCC v6 and v7","Stage IV Ovarian Cancer AJCC v8","Stage IVA Ovarian Cancer AJCC v8","Stage IVB Ovarian Cancer AJCC v8",[56],{"nctId":522,"briefTitle":523,"status":112,"phases":646,"primaryCompletion":525,"completion":526,"start":527,"enrollment":365,"conditions":647,"interventions":648},[89],[529,530],[459,532,533,439,56],{"nctId":650,"briefTitle":651,"status":268,"phases":652,"primaryCompletion":653,"completion":209,"start":654,"enrollment":655,"conditions":656,"interventions":668},"NCT03257163","Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer",[89],"2026-08-31","2017-09-29",40,[657,658,659,660,661,662,663,664,665,666,667],"Epstein-Barr Virus Positive","Gastric Adenocarcinoma","Mismatch Repair Protein Deficiency","Stage IB Gastric Cancer AJCC v7","Stage II Gastric Cancer AJCC v7","Stage IIA Gastric Cancer AJCC v7","Stage IIB Gastric Cancer AJCC v7","Stage III Gastric Cancer AJCC v7","Stage IIIA Gastric Cancer AJCC v7","Stage IIIB Gastric Cancer AJCC v7","Stage IIIC Gastric Cancer AJCC v7",[669,56],"Capecitabine",{"trials":671,"activeCount":100},[],{"trials":673,"activeCount":100},[],{"trials":675,"activeCount":100},[],{"intervention":459,"totalTrials":677,"cells":678},5,{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":691,"PHASE3":706,"PHASE4":708,"NA":710},{"trials":680,"activeCount":100},[],{"trials":682,"activeCount":100},[683,687],{"nctId":446,"briefTitle":447,"status":448,"phases":684,"primaryCompletion":450,"completion":451,"start":452,"enrollment":453,"conditions":685,"interventions":686},[88],[455,456,457],[439,459,56],{"nctId":461,"briefTitle":462,"status":463,"phases":688,"primaryCompletion":465,"completion":465,"start":466,"enrollment":467,"conditions":689,"interventions":690},[88],[469,470],[472,459,439],{"trials":692,"activeCount":705,"soonestReadout":40},[693,697,701],{"nctId":476,"briefTitle":477,"status":448,"phases":694,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":695,"interventions":696},[89],[483,484,485],[459,439,487,488],{"nctId":38,"briefTitle":39,"status":268,"phases":698,"primaryCompletion":40,"completion":504,"start":505,"enrollment":506,"conditions":699,"interventions":700},[89],[508,509,510,511,512,513,514,515,516],[41,518,519,520],{"nctId":522,"briefTitle":523,"status":112,"phases":702,"primaryCompletion":525,"completion":526,"start":527,"enrollment":365,"conditions":703,"interventions":704},[89],[529,530],[459,532,533,439,56],2,{"trials":707,"activeCount":100},[],{"trials":709,"activeCount":100},[],{"trials":711,"activeCount":100},[],{"intervention":713,"totalTrials":705,"cells":714},"Tirzepatide",{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":719,"PHASE3":742,"PHASE4":744,"NA":746},{"trials":716,"activeCount":100},[],{"trials":718,"activeCount":100},[],{"trials":720,"activeCount":705,"soonestReadout":736},[721,732],{"nctId":722,"briefTitle":723,"status":724,"phases":725,"primaryCompletion":726,"completion":726,"start":727,"enrollment":728,"conditions":729,"interventions":731},"NCT07605247","Tirzepatide in the Treatment of Endometrial Cancer","NOT_YET_RECRUITING",[89],"2028-01","2026-06-01",30,[730],"Endometrial Cancer",[713],{"nctId":733,"briefTitle":734,"status":112,"phases":735,"primaryCompletion":736,"completion":736,"start":737,"enrollment":655,"conditions":738,"interventions":741},"NCT06518837","Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive\u002FHER2 Negative Breast Cancer",[89],"2027-09-30","2024-10-30",[739,740],"Hormone Receptor-Positive Breast Cancer","HER2-Negative Breast Cancer",[713],{"trials":743,"activeCount":100},[],{"trials":745,"activeCount":100},[],{"trials":747,"activeCount":100},[],{"intervention":749,"totalTrials":705,"cells":750},"Temporo-masseteric Nerve Block",{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":778,"PHASE4":780,"NA":782},{"trials":752,"activeCount":100},[],{"trials":754,"activeCount":100},[],{"trials":756,"activeCount":705,"soonestReadout":164},[757,769],{"nctId":758,"briefTitle":759,"status":724,"phases":760,"primaryCompletion":761,"completion":762,"start":763,"enrollment":211,"conditions":764,"interventions":767},"NCT07094542","Jaw Muscle Pain Post Wisdom Molar Surgery",[89],"2029-11","2030-05","2026-05",[213,765,766],"Impacted Third Molar Tooth","Muscle Pain",[749,768],"Oral Pain Medications only",{"nctId":770,"briefTitle":771,"status":112,"phases":772,"primaryCompletion":164,"completion":773,"start":774,"enrollment":9,"conditions":775,"interventions":777},"NCT05335070","Reducing Pain From Wisdom Molar Extractions",[89],"2026-12","2022-09-13",[776],"Acute Pain",[749],{"trials":779,"activeCount":100},[],{"trials":781,"activeCount":100},[],{"trials":783,"activeCount":100},[],{"intervention":76,"totalTrials":705,"cells":785},{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":802,"PHASE4":804,"NA":818},{"trials":787,"activeCount":100},[],{"trials":789,"activeCount":100},[],{"trials":791,"activeCount":96,"soonestReadout":75},[792],{"nctId":73,"briefTitle":74,"status":112,"phases":793,"primaryCompletion":75,"completion":763,"start":794,"enrollment":365,"conditions":795,"interventions":801},[89],"2024-11-13",[796,797,798,799,800],"Post Operative Analgesia","Bariatric Surgery","Bariatric Surgery (Gastric Bypass)","Bariatric Surgery Patients","Perioperative Analgesia",[76],{"trials":803,"activeCount":100},[],{"trials":805,"activeCount":100},[806],{"nctId":807,"briefTitle":808,"status":463,"phases":809,"primaryCompletion":810,"completion":811,"start":812,"enrollment":813,"conditions":814,"interventions":816},"NCT02832687","Multi-dose Acetaminophen for Patients Undergoing General Anesthesia",[91],"2020-09-01","2020-12-31","2017-06-19",88,[815],"Recovery Following Cholecystectomy",[76,817],"normal saline",{"trials":819,"activeCount":100},[],{"intervention":501,"totalTrials":705,"cells":821},{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":841,"PHASE4":843,"NA":845},{"trials":823,"activeCount":100},[],{"trials":825,"activeCount":100},[],{"trials":827,"activeCount":96,"soonestReadout":296},[828,832],{"nctId":490,"briefTitle":491,"status":112,"phases":829,"primaryCompletion":296,"completion":493,"start":494,"enrollment":495,"conditions":830,"interventions":831},[89],[497],[499,500,501,439],{"nctId":833,"briefTitle":834,"status":463,"phases":835,"primaryCompletion":836,"completion":836,"start":837,"enrollment":22,"conditions":838,"interventions":839},"NCT00176631","Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy",[89],"2008-05","2007-09",[18],[840],"docetaxel",{"trials":842,"activeCount":100},[],{"trials":844,"activeCount":100},[],{"trials":846,"activeCount":100},[],{"intervention":669,"totalTrials":705,"cells":848},{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":872,"PHASE4":874,"NA":876},{"trials":850,"activeCount":100},[],{"trials":852,"activeCount":100},[],{"trials":854,"activeCount":96,"soonestReadout":653},[855,859],{"nctId":650,"briefTitle":651,"status":268,"phases":856,"primaryCompletion":653,"completion":209,"start":654,"enrollment":655,"conditions":857,"interventions":858},[89],[657,658,659,660,661,662,663,664,665,666,667],[669,56],{"nctId":860,"briefTitle":861,"status":463,"phases":862,"primaryCompletion":863,"completion":864,"start":865,"enrollment":866,"conditions":867,"interventions":870},"NCT00496366","Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2\u002FNeu-positive Breast Cancer",[89],"2009-12-31","2017-03-20","2007-07-23",11,[15,543,868,869],"Advanced Breast Cancer","HER2\u002FNeu-positive Breast Cancer",[669,871],"Lapatinib",{"trials":873,"activeCount":100},[],{"trials":875,"activeCount":100},[],{"trials":877,"activeCount":100},[],{"intervention":85,"totalTrials":96,"cells":879},{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":893,"PHASE4":895,"NA":897},{"trials":881,"activeCount":100},[],{"trials":883,"activeCount":100},[],{"trials":885,"activeCount":96,"soonestReadout":84},[886],{"nctId":82,"briefTitle":83,"status":112,"phases":887,"primaryCompletion":84,"completion":525,"start":888,"enrollment":495,"conditions":889,"interventions":892},[89],"2023-05-17",[890,891],"Colon Cancer","Rectal Cancer",[85],{"trials":894,"activeCount":100},[],{"trials":896,"activeCount":100},[],{"trials":898,"activeCount":100},[],{"intervention":900,"totalTrials":96,"cells":901},"Superior laryngeal nerve block - Intervention",{"EARLY_PHASE1":902,"PHASE1":904,"PHASE2":906,"PHASE3":920,"PHASE4":922,"NA":924},{"trials":903,"activeCount":100},[],{"trials":905,"activeCount":100},[],{"trials":907,"activeCount":96,"soonestReadout":773},[908],{"nctId":909,"briefTitle":910,"status":112,"phases":911,"primaryCompletion":773,"completion":773,"start":912,"enrollment":913,"conditions":914,"interventions":918},"NCT06734975","Effect of Superior Laryngeal Nerve Blocks on Patient Outcomes in Laryngeal Surgery",[89],"2025-07-11",28,[915,916,917],"Vocal Cord Disease","Vocal Cord Polyp","Vocal Cord Cyst",[900,919],"Superior laryngeal nerve block - Placebo",{"trials":921,"activeCount":100},[],{"trials":923,"activeCount":100},[],{"trials":925,"activeCount":100},[],{"intervention":919,"totalTrials":96,"cells":927},{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":932,"PHASE3":938,"PHASE4":940,"NA":942},{"trials":929,"activeCount":100},[],{"trials":931,"activeCount":100},[],{"trials":933,"activeCount":96,"soonestReadout":773},[934],{"nctId":909,"briefTitle":910,"status":112,"phases":935,"primaryCompletion":773,"completion":773,"start":912,"enrollment":913,"conditions":936,"interventions":937},[89],[915,916,917],[900,919],{"trials":939,"activeCount":100},[],{"trials":941,"activeCount":100},[],{"trials":943,"activeCount":100},[],{"intervention":945,"totalTrials":96,"cells":946},"Sequential Gemcitabine and Jelmyto Treatment",{"EARLY_PHASE1":947,"PHASE1":949,"PHASE2":951,"PHASE3":965,"PHASE4":967,"NA":969},{"trials":948,"activeCount":100},[],{"trials":950,"activeCount":100},[],{"trials":952,"activeCount":96,"soonestReadout":957},[953],{"nctId":954,"briefTitle":955,"status":112,"phases":956,"primaryCompletion":957,"completion":958,"start":959,"enrollment":913,"conditions":960,"interventions":964},"NCT06822010","SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma",[89],"2028-04-01","2029-04-01","2026-03-06",[961,962,963],"Urinary Bladder Cancer","Upper Tract Urothelial Cancer","Urothelial Cancer",[945],{"trials":966,"activeCount":100},[],{"trials":968,"activeCount":100},[],{"trials":970,"activeCount":100},[],{"intervention":972,"totalTrials":96,"cells":973},"Semaglutide",{"EARLY_PHASE1":974,"PHASE1":976,"PHASE2":978,"PHASE3":993,"PHASE4":995,"NA":997},{"trials":975,"activeCount":100},[],{"trials":977,"activeCount":100},[],{"trials":979,"activeCount":96,"soonestReadout":984},[980],{"nctId":981,"briefTitle":982,"status":112,"phases":983,"primaryCompletion":984,"completion":985,"start":986,"enrollment":211,"conditions":987,"interventions":991},"NCT06072963","COMMETS- Combination MCI Metabolic Syndrome",[89],"2027-12-01","2028-12-01","2024-01-30",[988,989,990],"Alzheimer Disease","Mild Cognitive Impairment","Metabolic Syndrome",[972,992],"Intranasal insulin",{"trials":994,"activeCount":100},[],{"trials":996,"activeCount":100},[],{"trials":998,"activeCount":100},[],{"intervention":992,"totalTrials":96,"cells":1000},{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1005,"PHASE3":1011,"PHASE4":1013,"NA":1015},{"trials":1002,"activeCount":100},[],{"trials":1004,"activeCount":100},[],{"trials":1006,"activeCount":96,"soonestReadout":984},[1007],{"nctId":981,"briefTitle":982,"status":112,"phases":1008,"primaryCompletion":984,"completion":985,"start":986,"enrollment":211,"conditions":1009,"interventions":1010},[89],[988,989,990],[972,992],{"trials":1012,"activeCount":100},[],{"trials":1014,"activeCount":100},[],{"trials":1016,"activeCount":100},[],{"intervention":61,"totalTrials":96,"cells":1018},{"EARLY_PHASE1":1019,"PHASE1":1021,"PHASE2":1023,"PHASE3":1035,"PHASE4":1037,"NA":1039},{"trials":1020,"activeCount":100},[],{"trials":1022,"activeCount":100},[],{"trials":1024,"activeCount":96,"soonestReadout":60},[1025],{"nctId":58,"briefTitle":59,"status":268,"phases":1026,"primaryCompletion":60,"completion":1027,"start":1028,"enrollment":1029,"conditions":1030,"interventions":1034},[89],"2026-03","2016-02",48,[1031,1032,21,1033],"Autism","Autistic Disorder","Autistic Behavior",[61],{"trials":1036,"activeCount":100},[],{"trials":1038,"activeCount":100},[],{"trials":1040,"activeCount":100},[],{"intervention":1042,"totalTrials":96,"cells":1043},"Temporomasseteric Nerve Block",{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1048,"PHASE3":1059,"PHASE4":1061,"NA":1063},{"trials":1045,"activeCount":100},[],{"trials":1047,"activeCount":100},[],{"trials":1049,"activeCount":96,"soonestReadout":1054},[1050],{"nctId":1051,"briefTitle":1052,"status":112,"phases":1053,"primaryCompletion":1054,"completion":773,"start":1055,"enrollment":9,"conditions":1056,"interventions":1058},"NCT05507164","Characterization of the Temporo-masseteric Nerve Block (TMNB) in Healthy Subjects",[89],"2026-09","2022-10-10",[1057],"Occlusion",[1042],{"trials":1060,"activeCount":100},[],{"trials":1062,"activeCount":100},[],{"trials":1064,"activeCount":100},[],{"intervention":1066,"totalTrials":96,"cells":1067},"Abiraterone Acetate",{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1089,"PHASE4":1091,"NA":1093},{"trials":1069,"activeCount":100},[],{"trials":1071,"activeCount":100},[],{"trials":1073,"activeCount":96,"soonestReadout":1078},[1074],{"nctId":1075,"briefTitle":1076,"status":268,"phases":1077,"primaryCompletion":1078,"completion":1079,"start":1080,"enrollment":1081,"conditions":1082,"interventions":1085},"NCT02949284","Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery",[89],"2026-06","2027-06","2017-06-20",90,[1083,1084],"Stage II Prostate Adenocarcinoma","Stage III Prostate Adenocarcinoma",[1066,1086,1087,1088],"Androgen Receptor Antagonist ARN-509","Gonadotropin-releasing Hormone Analog","Prednisone",{"trials":1090,"activeCount":100},[],{"trials":1092,"activeCount":100},[],{"trials":1094,"activeCount":100},[],{"intervention":1086,"totalTrials":96,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1107,"PHASE4":1109,"NA":1111},{"trials":1098,"activeCount":100},[],{"trials":1100,"activeCount":100},[],{"trials":1102,"activeCount":96,"soonestReadout":1078},[1103],{"nctId":1075,"briefTitle":1076,"status":268,"phases":1104,"primaryCompletion":1078,"completion":1079,"start":1080,"enrollment":1081,"conditions":1105,"interventions":1106},[89],[1083,1084],[1066,1086,1087,1088],{"trials":1108,"activeCount":100},[],{"trials":1110,"activeCount":100},[],{"trials":1112,"activeCount":100},[],{"intervention":1087,"totalTrials":96,"cells":1114},{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1119,"PHASE3":1125,"PHASE4":1127,"NA":1129},{"trials":1116,"activeCount":100},[],{"trials":1118,"activeCount":100},[],{"trials":1120,"activeCount":96,"soonestReadout":1078},[1121],{"nctId":1075,"briefTitle":1076,"status":268,"phases":1122,"primaryCompletion":1078,"completion":1079,"start":1080,"enrollment":1081,"conditions":1123,"interventions":1124},[89],[1083,1084],[1066,1086,1087,1088],{"trials":1126,"activeCount":100},[],{"trials":1128,"activeCount":100},[],{"trials":1130,"activeCount":100},[],{"intervention":1088,"totalTrials":96,"cells":1132},{"EARLY_PHASE1":1133,"PHASE1":1135,"PHASE2":1137,"PHASE3":1143,"PHASE4":1145,"NA":1147},{"trials":1134,"activeCount":100},[],{"trials":1136,"activeCount":100},[],{"trials":1138,"activeCount":96,"soonestReadout":1078},[1139],{"nctId":1075,"briefTitle":1076,"status":268,"phases":1140,"primaryCompletion":1078,"completion":1079,"start":1080,"enrollment":1081,"conditions":1141,"interventions":1142},[89],[1083,1084],[1066,1086,1087,1088],{"trials":1144,"activeCount":100},[],{"trials":1146,"activeCount":100},[],{"trials":1148,"activeCount":100},[],{"intervention":499,"totalTrials":96,"cells":1150},{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1161,"PHASE4":1163,"NA":1165},{"trials":1152,"activeCount":100},[],{"trials":1154,"activeCount":100},[],{"trials":1156,"activeCount":96,"soonestReadout":296},[1157],{"nctId":490,"briefTitle":491,"status":112,"phases":1158,"primaryCompletion":296,"completion":493,"start":494,"enrollment":495,"conditions":1159,"interventions":1160},[89],[497],[499,500,501,439],{"trials":1162,"activeCount":100},[],{"trials":1164,"activeCount":100},[],{"trials":1166,"activeCount":100},[],{"intervention":500,"totalTrials":96,"cells":1168},{"EARLY_PHASE1":1169,"PHASE1":1171,"PHASE2":1173,"PHASE3":1179,"PHASE4":1181,"NA":1183},{"trials":1170,"activeCount":100},[],{"trials":1172,"activeCount":100},[],{"trials":1174,"activeCount":96,"soonestReadout":296},[1175],{"nctId":490,"briefTitle":491,"status":112,"phases":1176,"primaryCompletion":296,"completion":493,"start":494,"enrollment":495,"conditions":1177,"interventions":1178},[89],[497],[499,500,501,439],{"trials":1180,"activeCount":100},[],{"trials":1182,"activeCount":100},[],{"trials":1184,"activeCount":100},[],{"intervention":1186,"totalTrials":96,"cells":1187},"EXTERNAL BEAM RADIATION",{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1205,"PHASE4":1207,"NA":1209},{"trials":1189,"activeCount":100},[],{"trials":1191,"activeCount":100},[],{"trials":1193,"activeCount":96,"soonestReadout":1198},[1194],{"nctId":1195,"briefTitle":1196,"status":112,"phases":1197,"primaryCompletion":1198,"completion":1198,"start":1199,"enrollment":1200,"conditions":1201,"interventions":1204},"NCT05419518","Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas",[89],"2027-04-01","2023-03-16",124,[1202,1203],"Neoplasm Metastases","Metastases, Neoplasm",[1186],{"trials":1206,"activeCount":100},[],{"trials":1208,"activeCount":100},[],{"trials":1210,"activeCount":100},[],{"intervention":80,"totalTrials":96,"cells":1212},{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1225,"PHASE4":1227,"NA":1229},{"trials":1214,"activeCount":100},[],{"trials":1216,"activeCount":100},[],{"trials":1218,"activeCount":96,"soonestReadout":75},[1219],{"nctId":78,"briefTitle":79,"status":112,"phases":1220,"primaryCompletion":75,"completion":1221,"start":1222,"enrollment":1029,"conditions":1223,"interventions":1224},[89],"2026-08","2024-03-11",[776],[80],{"trials":1226,"activeCount":100},[],{"trials":1228,"activeCount":100},[],{"trials":1230,"activeCount":100},[],{"intervention":51,"totalTrials":96,"cells":1232},{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1237,"PHASE3":1252,"PHASE4":1254,"NA":1256},{"trials":1234,"activeCount":100},[],{"trials":1236,"activeCount":100},[],{"trials":1238,"activeCount":96,"soonestReadout":50},[1239],{"nctId":48,"briefTitle":49,"status":268,"phases":1240,"primaryCompletion":50,"completion":1241,"start":1242,"enrollment":495,"conditions":1243,"interventions":1250},[89],"2026-03-27","2019-02-12",[1244,1245,1246,1247,1248,1249],"Metastatic Colorectal Carcinoma","Recurrent Colon Carcinoma","Refractory Colorectal Carcinoma","Stage IV Colon Cancer AJCC v7","Stage IVA Colon Cancer AJCC v7","Stage IVB Colon Cancer AJCC v7",[51,1251],"Trifluridine and Tipiracil Hydrochloride",{"trials":1253,"activeCount":100},[],{"trials":1255,"activeCount":100},[],{"trials":1257,"activeCount":100},[],{"intervention":1251,"totalTrials":96,"cells":1259},{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1264,"PHASE3":1270,"PHASE4":1272,"NA":1274},{"trials":1261,"activeCount":100},[],{"trials":1263,"activeCount":100},[],{"trials":1265,"activeCount":96,"soonestReadout":50},[1266],{"nctId":48,"briefTitle":49,"status":268,"phases":1267,"primaryCompletion":50,"completion":1241,"start":1242,"enrollment":495,"conditions":1268,"interventions":1269},[89],[1244,1245,1246,1247,1248,1249],[51,1251],{"trials":1271,"activeCount":100},[],{"trials":1273,"activeCount":100},[],{"trials":1275,"activeCount":100},[],{"intervention":41,"totalTrials":96,"cells":1277},{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1282,"PHASE3":1288,"PHASE4":1290,"NA":1292},{"trials":1279,"activeCount":100},[],{"trials":1281,"activeCount":100},[],{"trials":1283,"activeCount":96,"soonestReadout":40},[1284],{"nctId":38,"briefTitle":39,"status":268,"phases":1285,"primaryCompletion":40,"completion":504,"start":505,"enrollment":506,"conditions":1286,"interventions":1287},[89],[508,509,510,511,512,513,514,515,516],[41,518,519,520],{"trials":1289,"activeCount":100},[],{"trials":1291,"activeCount":100},[],{"trials":1293,"activeCount":100},[],{"intervention":518,"totalTrials":96,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1306,"PHASE4":1308,"NA":1310},{"trials":1297,"activeCount":100},[],{"trials":1299,"activeCount":100},[],{"trials":1301,"activeCount":96,"soonestReadout":40},[1302],{"nctId":38,"briefTitle":39,"status":268,"phases":1303,"primaryCompletion":40,"completion":504,"start":505,"enrollment":506,"conditions":1304,"interventions":1305},[89],[508,509,510,511,512,513,514,515,516],[41,518,519,520],{"trials":1307,"activeCount":100},[],{"trials":1309,"activeCount":100},[],{"trials":1311,"activeCount":100},[],{"intervention":768,"totalTrials":96,"cells":1313},{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1324,"PHASE4":1326,"NA":1328},{"trials":1315,"activeCount":100},[],{"trials":1317,"activeCount":100},[],{"trials":1319,"activeCount":96,"soonestReadout":761},[1320],{"nctId":758,"briefTitle":759,"status":724,"phases":1321,"primaryCompletion":761,"completion":762,"start":763,"enrollment":211,"conditions":1322,"interventions":1323},[89],[213,765,766],[749,768],{"trials":1325,"activeCount":100},[],{"trials":1327,"activeCount":100},[],{"trials":1329,"activeCount":100},[],{"intervention":532,"totalTrials":96,"cells":1331},{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1342,"PHASE4":1344,"NA":1346},{"trials":1333,"activeCount":100},[],{"trials":1335,"activeCount":100},[],{"trials":1337,"activeCount":96,"soonestReadout":525},[1338],{"nctId":522,"briefTitle":523,"status":112,"phases":1339,"primaryCompletion":525,"completion":526,"start":527,"enrollment":365,"conditions":1340,"interventions":1341},[89],[529,530],[459,532,533,439,56],{"trials":1343,"activeCount":100},[],{"trials":1345,"activeCount":100},[],{"trials":1347,"activeCount":100},[],{"intervention":533,"totalTrials":96,"cells":1349},{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1360,"PHASE4":1362,"NA":1364},{"trials":1351,"activeCount":100},[],{"trials":1353,"activeCount":100},[],{"trials":1355,"activeCount":96,"soonestReadout":525},[1356],{"nctId":522,"briefTitle":523,"status":112,"phases":1357,"primaryCompletion":525,"completion":526,"start":527,"enrollment":365,"conditions":1358,"interventions":1359},[89],[529,530],[459,532,533,439,56],{"trials":1361,"activeCount":100},[],{"trials":1363,"activeCount":100},[],{"trials":1365,"activeCount":100},[],{"intervention":1367,"totalTrials":96,"cells":1368},"Tislelizumab",{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1385,"PHASE4":1387,"NA":1389},{"trials":1370,"activeCount":100},[],{"trials":1372,"activeCount":100},[],{"trials":1374,"activeCount":96,"soonestReadout":295},[1375],{"nctId":1376,"briefTitle":1377,"status":112,"phases":1378,"primaryCompletion":295,"completion":295,"start":1379,"enrollment":1380,"conditions":1381,"interventions":1384},"NCT05366829","Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma",[89],"2022-07-25",35,[1382,1383],"Carcinoma, Hepatocellular","Liver Cell Carcinoma",[1367],{"trials":1386,"activeCount":100},[],{"trials":1388,"activeCount":100},[],{"trials":1390,"activeCount":100},[],{"intervention":1392,"totalTrials":96,"cells":1393},"Four week alternating FOLFOX and FOLFIRI",{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1398,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1395,"activeCount":100},[],{"trials":1397,"activeCount":100},[],{"trials":1399,"activeCount":96,"soonestReadout":1404},[1400],{"nctId":1401,"briefTitle":1402,"status":112,"phases":1403,"primaryCompletion":1404,"completion":1404,"start":1405,"enrollment":1406,"conditions":1407,"interventions":1409},"NCT05332002","sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)",[89],"2026-08-01","2022-07-13",38,[1408],"Gastro-Intestinal Cancer",[1392],{"trials":1411,"activeCount":100},[],{"trials":1413,"activeCount":100},[],{"trials":1415,"activeCount":100},[],{"intervention":1417,"totalTrials":96,"cells":1418},"Lipitor 40mg",{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1436,"PHASE4":1438,"NA":1440},{"trials":1420,"activeCount":100},[],{"trials":1422,"activeCount":100},[],{"trials":1424,"activeCount":96,"soonestReadout":409},[1425],{"nctId":1426,"briefTitle":1427,"status":112,"phases":1428,"primaryCompletion":409,"completion":1429,"start":1430,"enrollment":1431,"conditions":1432,"interventions":1435},"NCT05559164","Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted",[89],"2027-03-01","2022-09-19",60,[1433,1434],"Cardiac Toxicity","Early-stage Breast Cancer",[1417],{"trials":1437,"activeCount":100},[],{"trials":1439,"activeCount":100},[],{"trials":1441,"activeCount":100},[],{"intervention":1443,"totalTrials":96,"cells":1444},"Twin block",{"EARLY_PHASE1":1445,"PHASE1":1447,"PHASE2":1449,"PHASE3":1460,"PHASE4":1462,"NA":1464},{"trials":1446,"activeCount":100},[],{"trials":1448,"activeCount":100},[],{"trials":1450,"activeCount":96,"soonestReadout":164},[1451],{"nctId":1452,"briefTitle":1453,"status":724,"phases":1454,"primaryCompletion":164,"completion":1455,"start":1456,"enrollment":1457,"conditions":1458,"interventions":1459},"NCT04414917","Reducing Opioid Use and Misuse After Wisdom Molar Extractions",[89],"2027-04","2024-11",133,[367],[1443],{"trials":1461,"activeCount":100},[],{"trials":1463,"activeCount":100},[],{"trials":1465,"activeCount":100},[],{"intervention":71,"totalTrials":96,"cells":1467},{"EARLY_PHASE1":1468,"PHASE1":1470,"PHASE2":1472,"PHASE3":1480,"PHASE4":1482,"NA":1484},{"trials":1469,"activeCount":100},[],{"trials":1471,"activeCount":100},[],{"trials":1473,"activeCount":96,"soonestReadout":70},[1474],{"nctId":68,"briefTitle":69,"status":112,"phases":1475,"primaryCompletion":70,"completion":208,"start":1476,"enrollment":495,"conditions":1477,"interventions":1479},[89],"2023-03-01",[1478],"Preterm Birth",[71],{"trials":1481,"activeCount":100},[],{"trials":1483,"activeCount":100},[],{"trials":1485,"activeCount":100},[],{"intervention":1487,"totalTrials":96,"cells":1488},"oral colchicine(0.6 mg) once a day",{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1501,"PHASE3":1503,"PHASE4":1505,"NA":1507},{"trials":1490,"activeCount":100},[],{"trials":1492,"activeCount":96,"soonestReadout":1078},[1493],{"nctId":1494,"briefTitle":1495,"status":268,"phases":1496,"primaryCompletion":1078,"completion":295,"start":1497,"enrollment":728,"conditions":1498,"interventions":1500},"NCT05335148","Study to Evaluate the Safety of Colchicine",[88],"2022-05-10",[1499],"Radiation Therapy",[1487],{"trials":1502,"activeCount":100},[],{"trials":1504,"activeCount":100},[],{"trials":1506,"activeCount":100},[],{"trials":1508,"activeCount":100},[],{"intervention":1510,"totalTrials":96,"cells":1511},"autologous fecal matter transplant",{"EARLY_PHASE1":1512,"PHASE1":1514,"PHASE2":1526,"PHASE3":1528,"PHASE4":1530,"NA":1532},{"trials":1513,"activeCount":100},[],{"trials":1515,"activeCount":96,"soonestReadout":1520},[1516],{"nctId":1517,"briefTitle":1518,"status":112,"phases":1519,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":117,"conditions":1523,"interventions":1525},"NCT06609980","Restoration of Antibiotics Related Infant Microbiota Perturbations by Autologous Fecal Transplant",[88],"2028-08-01","2028-09-01","2024-08-01",[1524],"Antibiotic Treatment",[1510],{"trials":1527,"activeCount":100},[],{"trials":1529,"activeCount":100},[],{"trials":1531,"activeCount":100},[],{"trials":1533,"activeCount":100},[],{"intervention":1535,"totalTrials":96,"cells":1536},"Intravenous immune globulin G",{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1553,"PHASE3":1555,"PHASE4":1557,"NA":1559},{"trials":1538,"activeCount":100},[],{"trials":1540,"activeCount":96,"soonestReadout":1545},[1541],{"nctId":1542,"briefTitle":1543,"status":112,"phases":1544,"primaryCompletion":1545,"completion":1545,"start":1546,"enrollment":9,"conditions":1547,"interventions":1551},"NCT05584631","IVIG vs SCIG in CIDP",[88],"2026-12-01","2022-09-11",[1548,1549,1550],"CIDP","Immunoglobulin Deficiency","Chronic Inflammatory Demyelinating Polyneuropathy",[1535,1552],"Subcutaneous immune globulin G",{"trials":1554,"activeCount":100},[],{"trials":1556,"activeCount":100},[],{"trials":1558,"activeCount":100},[],{"trials":1560,"activeCount":100},[],{"intervention":1552,"totalTrials":96,"cells":1562},{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1571,"PHASE3":1573,"PHASE4":1575,"NA":1577},{"trials":1564,"activeCount":100},[],{"trials":1566,"activeCount":96,"soonestReadout":1545},[1567],{"nctId":1542,"briefTitle":1543,"status":112,"phases":1568,"primaryCompletion":1545,"completion":1545,"start":1546,"enrollment":9,"conditions":1569,"interventions":1570},[88],[1548,1549,1550],[1535,1552],{"trials":1572,"activeCount":100},[],{"trials":1574,"activeCount":100},[],{"trials":1576,"activeCount":100},[],{"trials":1578,"activeCount":100},[],{"intervention":1580,"totalTrials":96,"cells":1581},"Guanfacine pharmacotherapy",{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1597,"PHASE3":1599,"PHASE4":1601,"NA":1603},{"trials":1583,"activeCount":100},[],{"trials":1585,"activeCount":96,"soonestReadout":653},[1586],{"nctId":1587,"briefTitle":1588,"status":112,"phases":1589,"primaryCompletion":653,"completion":1590,"start":1591,"enrollment":1592,"conditions":1593,"interventions":1596},"NCT06642181","Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder",[88],"2026-09-30","2025-07-15",224,[1594,1595,413],"Mindfulness","Guanfacine",[1580],{"trials":1598,"activeCount":100},[],{"trials":1600,"activeCount":100},[],{"trials":1602,"activeCount":100},[],{"trials":1604,"activeCount":100},[],{"intervention":1606,"totalTrials":96,"cells":1607},"Loratadine",{"EARLY_PHASE1":1608,"PHASE1":1620,"PHASE2":1622,"PHASE3":1624,"PHASE4":1626,"NA":1628},{"trials":1609,"activeCount":96,"soonestReadout":653},[1610],{"nctId":1611,"briefTitle":1612,"status":112,"phases":1613,"primaryCompletion":653,"completion":1614,"start":1615,"enrollment":1616,"conditions":1617,"interventions":1619},"NCT04211259","Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization",[87],"2027-06-30","2022-04-18",70,[1618],"Plasma Cell Myeloma",[1606],{"trials":1621,"activeCount":100},[],{"trials":1623,"activeCount":100},[],{"trials":1625,"activeCount":100},[],{"trials":1627,"activeCount":100},[],{"trials":1629,"activeCount":100},[],{"intervention":1631,"totalTrials":96,"cells":1632},"Neoadjuvant chemotherapy administered before surgical extraction of a tumor",{"EARLY_PHASE1":1633,"PHASE1":1644,"PHASE2":1646,"PHASE3":1648,"PHASE4":1650,"NA":1652},{"trials":1634,"activeCount":96,"soonestReadout":1639},[1635],{"nctId":1636,"briefTitle":1637,"status":268,"phases":1638,"primaryCompletion":1639,"completion":1639,"start":1640,"enrollment":467,"conditions":1641,"interventions":1643},"NCT05333874","CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage",[87],"2027-11-28","2022-04-06",[1642],"Breast Cancer, Early-Onset",[1631],{"trials":1645,"activeCount":100},[],{"trials":1647,"activeCount":100},[],{"trials":1649,"activeCount":100},[],{"trials":1651,"activeCount":100},[],{"trials":1653,"activeCount":100},[],{"intervention":1655,"totalTrials":546,"cells":1656},"Saliva sample",{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1663,"PHASE4":1665,"NA":1667},{"trials":1658,"activeCount":100},[],{"trials":1660,"activeCount":100},[],{"trials":1662,"activeCount":100},[],{"trials":1664,"activeCount":100},[],{"trials":1666,"activeCount":100},[],{"trials":1668,"activeCount":546,"soonestReadout":296},[1669,1681,1696],{"nctId":1670,"briefTitle":1671,"status":112,"phases":1672,"primaryCompletion":1673,"completion":1674,"start":1675,"enrollment":1676,"conditions":1677,"interventions":1680},"NCT06773897","Rutgers University Study of the Genetics of Breast Cancer.",[],"2028-04-15","2028-04-30","2024-04-15",25000,[1678,1679,15],"Breast Cancer Risk","Breast Cancer Prevention",[1655],{"nctId":1682,"briefTitle":1683,"status":112,"phases":1684,"primaryCompletion":1685,"completion":1685,"start":1686,"enrollment":1687,"conditions":1688,"interventions":1695},"NCT07217535","Rutgers University Study of the Genetics of Kidney Disease",[],"2028-10-31","2026-04-23",50000,[1689,1690,1691,1692,1693,1694],"Kidney Disease","Kidney Disease, Chronic","Kidney Disease, End-Stage","Kidney Diseases","Kidney Diseases, Chronic","Kidney Diseases,Cystic",[1655],{"nctId":1697,"briefTitle":1698,"status":112,"phases":1699,"primaryCompletion":296,"completion":296,"start":1700,"enrollment":1701,"conditions":1702,"interventions":1711},"NCT07217522","Rutgers University Study of the Genetics of Pulmonary Hypertension",[],"2025-08-23",10000,[1703,1704,1705,1706,1707,1708,1709,1710],"Pulmonary Hypertension","Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)","Pulmonary Arterial Hypertension Associated With Connective Tissue Disease","Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder)","Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder)","Pulmonary Arterial Hypertension of Congenital Heart Disease","Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension",[1655],{"intervention":1713,"totalTrials":96,"cells":1714},"U-13C-glucose",{"EARLY_PHASE1":1715,"PHASE1":1717,"PHASE2":1719,"PHASE3":1721,"PHASE4":1723,"NA":1725},{"trials":1716,"activeCount":100},[],{"trials":1718,"activeCount":100},[],{"trials":1720,"activeCount":100},[],{"trials":1722,"activeCount":100},[],{"trials":1724,"activeCount":100},[],{"trials":1726,"activeCount":96,"soonestReadout":208},[1727],{"nctId":1728,"briefTitle":1729,"status":112,"phases":1730,"primaryCompletion":208,"completion":493,"start":1731,"enrollment":1732,"conditions":1733,"interventions":1734},"NCT05736367","Investigating the Metabolic Pathways in Hormone Receptor Positive\u002FHER2 Negative Breast Cancer",[92],"2024-11-15",16,[15],[1713],{"intervention":1736,"totalTrials":96,"cells":1737},"Glycerol",{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1742,"PHASE3":1744,"PHASE4":1746,"NA":1748},{"trials":1739,"activeCount":100},[],{"trials":1741,"activeCount":100},[],{"trials":1743,"activeCount":100},[],{"trials":1745,"activeCount":100},[],{"trials":1747,"activeCount":100},[],{"trials":1749,"activeCount":96,"soonestReadout":1754},[1750],{"nctId":1751,"briefTitle":1752,"status":724,"phases":1753,"primaryCompletion":1754,"completion":1755,"start":1756,"enrollment":1029,"conditions":1757,"interventions":1760},"NCT06955130","Lactate and Glycerol Contribution to Gluconeogenesis",[92],"2029-04-30","2030-04-30","2026-07-01",[1758,34,1759],"Type 2 Diabetes","Healthy",[1736,1761,1762],"Lactate","Glucose",{"intervention":1761,"totalTrials":96,"cells":1764},{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1769,"PHASE3":1771,"PHASE4":1773,"NA":1775},{"trials":1766,"activeCount":100},[],{"trials":1768,"activeCount":100},[],{"trials":1770,"activeCount":100},[],{"trials":1772,"activeCount":100},[],{"trials":1774,"activeCount":100},[],{"trials":1776,"activeCount":96,"soonestReadout":1754},[1777],{"nctId":1751,"briefTitle":1752,"status":724,"phases":1778,"primaryCompletion":1754,"completion":1755,"start":1756,"enrollment":1029,"conditions":1779,"interventions":1780},[92],[1758,34,1759],[1736,1761,1762],{"intervention":1762,"totalTrials":96,"cells":1782},{"EARLY_PHASE1":1783,"PHASE1":1785,"PHASE2":1787,"PHASE3":1789,"PHASE4":1791,"NA":1793},{"trials":1784,"activeCount":100},[],{"trials":1786,"activeCount":100},[],{"trials":1788,"activeCount":100},[],{"trials":1790,"activeCount":100},[],{"trials":1792,"activeCount":100},[],{"trials":1794,"activeCount":96,"soonestReadout":1754},[1795],{"nctId":1751,"briefTitle":1752,"status":724,"phases":1796,"primaryCompletion":1754,"completion":1755,"start":1756,"enrollment":1029,"conditions":1797,"interventions":1798},[92],[1758,34,1759],[1736,1761,1762],{"intervention":1800,"totalTrials":96,"cells":1801},"Insulin glargine alone",{"EARLY_PHASE1":1802,"PHASE1":1804,"PHASE2":1806,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1803,"activeCount":100},[],{"trials":1805,"activeCount":100},[],{"trials":1807,"activeCount":100},[],{"trials":1809,"activeCount":100},[],{"trials":1811,"activeCount":100},[],{"trials":1813,"activeCount":96,"soonestReadout":1818},[1814],{"nctId":1815,"briefTitle":1816,"status":112,"phases":1817,"primaryCompletion":1818,"completion":1819,"start":1820,"enrollment":1821,"conditions":1822,"interventions":1825},"NCT07171684","Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)",[92],"2026-10-01","2027-05-15","2025-11-26",176,[1823,1824],"Diabetes in Pregnancy","Gestational Diabetes",[1800,1826],"Insulin glargine + insulin lispro",{"intervention":1826,"totalTrials":96,"cells":1828},{"EARLY_PHASE1":1829,"PHASE1":1831,"PHASE2":1833,"PHASE3":1835,"PHASE4":1837,"NA":1839},{"trials":1830,"activeCount":100},[],{"trials":1832,"activeCount":100},[],{"trials":1834,"activeCount":100},[],{"trials":1836,"activeCount":100},[],{"trials":1838,"activeCount":100},[],{"trials":1840,"activeCount":96,"soonestReadout":1818},[1841],{"nctId":1815,"briefTitle":1816,"status":112,"phases":1842,"primaryCompletion":1818,"completion":1819,"start":1820,"enrollment":1821,"conditions":1843,"interventions":1844},[92],[1823,1824],[1800,1826],{"intervention":1846,"totalTrials":705,"cells":1847},"Ascorbic Acid",{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1864,"PHASE4":1866,"NA":1878},{"trials":1849,"activeCount":100},[],{"trials":1851,"activeCount":100},[],{"trials":1853,"activeCount":100},[1854],{"nctId":1855,"briefTitle":1856,"status":463,"phases":1857,"primaryCompletion":1858,"completion":1859,"start":1860,"enrollment":866,"conditions":1861,"interventions":1863},"NCT01587963","High Dose Vitamin C in the Critically Ill Patient",[89],"2014-02","2015-04","2013-02",[1862],"Shock",[1846],{"trials":1865,"activeCount":100},[],{"trials":1867,"activeCount":100},[1868],{"nctId":1869,"briefTitle":1870,"status":448,"phases":1871,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":1874,"conditions":1875,"interventions":1877},"NCT01167569","Study of High Dose Vitamin C On Outcome in Cardiac Surgery Patients",[91],"2013-04","2007-10",57,[1876],"Reperfusion Injury",[1846],{"trials":1879,"activeCount":100},[],{"intervention":817,"totalTrials":705,"cells":1881},{"EARLY_PHASE1":1882,"PHASE1":1884,"PHASE2":1886,"PHASE3":1888,"PHASE4":1890,"NA":1907},{"trials":1883,"activeCount":100},[],{"trials":1885,"activeCount":100},[],{"trials":1887,"activeCount":100},[],{"trials":1889,"activeCount":100},[],{"trials":1891,"activeCount":100},[1892,1896],{"nctId":807,"briefTitle":808,"status":463,"phases":1893,"primaryCompletion":810,"completion":811,"start":812,"enrollment":813,"conditions":1894,"interventions":1895},[91],[815],[76,817],{"nctId":1897,"briefTitle":1898,"status":1899,"phases":1900,"primaryCompletion":1901,"start":1902,"enrollment":100,"conditions":1903,"interventions":1905},"NCT00932386","Effects of Dexmedetomidine on Tourniquet Pain Associated With Lower Extremity Surgeries Under General Anesthesia","WITHDRAWN",[91],"2011-07","2009-07",[1904],"Orthopedic\u002FPodiatry Procedures",[1906,817],"Dexmedetomidine Hcl",{"trials":1908,"activeCount":100},[],{"intervention":1910,"totalTrials":96,"cells":1911},"Etanercept",{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1916,"PHASE3":1918,"PHASE4":1920,"NA":1932},{"trials":1913,"activeCount":100},[],{"trials":1915,"activeCount":100},[],{"trials":1917,"activeCount":100},[],{"trials":1919,"activeCount":100},[],{"trials":1921,"activeCount":100},[1922],{"nctId":1923,"briefTitle":1924,"status":463,"phases":1925,"primaryCompletion":1926,"completion":1926,"start":1927,"enrollment":677,"conditions":1928,"interventions":1930},"NCT03636373","Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout",[91],"2021-08-13","2019-10-25",[1929],"Gout Attack",[1910,1931],"Triamcinolone Acetonide",{"trials":1933,"activeCount":100},[],{"intervention":1931,"totalTrials":96,"cells":1935},{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1940,"PHASE3":1942,"PHASE4":1944,"NA":1950},{"trials":1937,"activeCount":100},[],{"trials":1939,"activeCount":100},[],{"trials":1941,"activeCount":100},[],{"trials":1943,"activeCount":100},[],{"trials":1945,"activeCount":100},[1946],{"nctId":1923,"briefTitle":1924,"status":463,"phases":1947,"primaryCompletion":1926,"completion":1926,"start":1927,"enrollment":677,"conditions":1948,"interventions":1949},[91],[1929],[1910,1931],{"trials":1951,"activeCount":100},[],{"intervention":1953,"totalTrials":96,"cells":1954},"tenofovir disoproxil and emtricitabine",{"EARLY_PHASE1":1955,"PHASE1":1957,"PHASE2":1959,"PHASE3":1961,"PHASE4":1963,"NA":1975},{"trials":1956,"activeCount":100},[],{"trials":1958,"activeCount":100},[],{"trials":1960,"activeCount":100},[],{"trials":1962,"activeCount":100},[],{"trials":1964,"activeCount":100},[1965],{"nctId":1966,"briefTitle":1967,"status":1968,"phases":1969,"primaryCompletion":60,"completion":60,"start":1970,"enrollment":1971,"conditions":1972,"interventions":1974},"NCT03058835","IN-US-276-1340: Pre-Exposure Prophylaxis to Prevent HIV Acquisition in US Women: A Demonstration Project","UNKNOWN",[91],"2016-09",125,[1973],"PrEP Adherence Monitoring",[1953],{"trials":1976,"activeCount":100},[],{"intervention":1978,"totalTrials":96,"cells":1979},"Amitriptyline",{"EARLY_PHASE1":1980,"PHASE1":1982,"PHASE2":1984,"PHASE3":1986,"PHASE4":1988,"NA":2000},{"trials":1981,"activeCount":100},[],{"trials":1983,"activeCount":100},[],{"trials":1985,"activeCount":100},[],{"trials":1987,"activeCount":100},[],{"trials":1989,"activeCount":100},[1990],{"nctId":1991,"briefTitle":1992,"status":463,"phases":1993,"primaryCompletion":1994,"completion":1994,"start":1995,"enrollment":22,"conditions":1996,"interventions":1999},"NCT02090998","Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines",[91],"2020-03-16","2014-05",[1997,1998],"Transformed Migraine","Chronic Daily Headache",[1978],{"trials":2001,"activeCount":100},[],{"intervention":2003,"totalTrials":96,"cells":2004},"TENIVAC",{"EARLY_PHASE1":2005,"PHASE1":2007,"PHASE2":2009,"PHASE3":2011,"PHASE4":2013,"NA":2033},{"trials":2006,"activeCount":100},[],{"trials":2008,"activeCount":100},[],{"trials":2010,"activeCount":100},[],{"trials":2012,"activeCount":100},[],{"trials":2014,"activeCount":100},[2015],{"nctId":2016,"briefTitle":2017,"status":448,"phases":2018,"primaryCompletion":2019,"completion":2019,"start":2020,"enrollment":9,"conditions":2021,"interventions":2032},"NCT06588530","PFAS Exposure and Immune Response to Vaccination in Adults",[91],"2025-01-08","2024-11-04",[2022,2023,2024,2025,2026,2027,2028,2029,2030,2031],"Innate Inflammatory Response","Vaccination","Diphtheria","Tetanus","Environmental Exposure","Vaccine","Antibodies","Adult","Immunity","Pollution; Exposure",[2003],{"trials":2034,"activeCount":100},[],{"intervention":1906,"totalTrials":96,"cells":2036},{"EARLY_PHASE1":2037,"PHASE1":2039,"PHASE2":2041,"PHASE3":2043,"PHASE4":2045,"NA":2051},{"trials":2038,"activeCount":100},[],{"trials":2040,"activeCount":100},[],{"trials":2042,"activeCount":100},[],{"trials":2044,"activeCount":100},[],{"trials":2046,"activeCount":100},[2047],{"nctId":1897,"briefTitle":1898,"status":1899,"phases":2048,"primaryCompletion":1901,"start":1902,"enrollment":100,"conditions":2049,"interventions":2050},[91],[1904],[1906,817],{"trials":2052,"activeCount":100},[],{"intervention":2054,"totalTrials":96,"cells":2055},"Low Dose Corticosteroids",{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2060,"PHASE3":2062,"PHASE4":2064,"NA":2077},{"trials":2057,"activeCount":100},[],{"trials":2059,"activeCount":100},[],{"trials":2061,"activeCount":100},[],{"trials":2063,"activeCount":100},[],{"trials":2065,"activeCount":100},[2066],{"nctId":2067,"briefTitle":2068,"status":463,"phases":2069,"primaryCompletion":2070,"completion":2070,"start":2071,"enrollment":2072,"conditions":2073,"interventions":2075},"NCT01742338","Dose of Corticosteroids in COPD",[91],"2020-03-15","2012-05-03",89,[2074],"COPD",[2054,2076],"High Dose Corticosteroids",{"trials":2078,"activeCount":100},[],{"intervention":2076,"totalTrials":96,"cells":2080},{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2085,"PHASE3":2087,"PHASE4":2089,"NA":2095},{"trials":2082,"activeCount":100},[],{"trials":2084,"activeCount":100},[],{"trials":2086,"activeCount":100},[],{"trials":2088,"activeCount":100},[],{"trials":2090,"activeCount":100},[2091],{"nctId":2067,"briefTitle":2068,"status":463,"phases":2092,"primaryCompletion":2070,"completion":2070,"start":2071,"enrollment":2072,"conditions":2093,"interventions":2094},[91],[2074],[2054,2076],{"trials":2096,"activeCount":100},[],{"intervention":2098,"totalTrials":96,"cells":2099},"Dexamethasone 8mg",{"EARLY_PHASE1":2100,"PHASE1":2102,"PHASE2":2104,"PHASE3":2106,"PHASE4":2108,"NA":2120},{"trials":2101,"activeCount":100},[],{"trials":2103,"activeCount":100},[],{"trials":2105,"activeCount":100},[],{"trials":2107,"activeCount":100},[],{"trials":2109,"activeCount":100},[2110],{"nctId":2111,"briefTitle":2112,"status":463,"phases":2113,"primaryCompletion":2114,"completion":2115,"start":2116,"enrollment":28,"conditions":2117,"interventions":2119},"NCT06074263","Search to Advance Limited Use of Opioids Pilot: Optimization of Non-Opioid Therapy With a Steroid",[91],"2024-09-30","2024-12-31","2023-11-27",[2118],"Pain Management",[2098],{"trials":2121,"activeCount":100},[],{"intervention":2123,"totalTrials":96,"cells":2124},"ibuprofen intravenous",{"EARLY_PHASE1":2125,"PHASE1":2127,"PHASE2":2129,"PHASE3":2131,"PHASE4":2133,"NA":2144},{"trials":2126,"activeCount":100},[],{"trials":2128,"activeCount":100},[],{"trials":2130,"activeCount":100},[],{"trials":2132,"activeCount":100},[],{"trials":2134,"activeCount":100},[2135],{"nctId":2136,"briefTitle":2137,"status":463,"phases":2138,"primaryCompletion":2139,"completion":2139,"start":2140,"enrollment":567,"conditions":2141,"interventions":2143},"NCT01200069","IV Ibuprofen for Post-Electroconvulsive Therapy Myalgia",[91],"2014-09","2010-07",[2142],"Depression, Myalgia",[2123],{"trials":2145,"activeCount":100},[],{"intervention":2147,"totalTrials":96,"cells":2148},"Metoclopramide",{"EARLY_PHASE1":2149,"PHASE1":2151,"PHASE2":2153,"PHASE3":2155,"PHASE4":2157,"NA":2173},{"trials":2150,"activeCount":100},[],{"trials":2152,"activeCount":100},[],{"trials":2154,"activeCount":100},[],{"trials":2156,"activeCount":100},[],{"trials":2158,"activeCount":100},[2159],{"nctId":2160,"briefTitle":2161,"status":448,"phases":2162,"primaryCompletion":2163,"completion":2164,"start":2165,"enrollment":2166,"conditions":2167,"interventions":2171},"NCT02959840","Acupuncture Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean",[91],"2016-03","2017-08-23","2015-07",180,[2168,2169,2170],"Nausea","Vomiting","Satisfaction",[2147,2172],"Ondansetron",{"trials":2174,"activeCount":100},[],{"intervention":2172,"totalTrials":96,"cells":2176},{"EARLY_PHASE1":2177,"PHASE1":2179,"PHASE2":2181,"PHASE3":2183,"PHASE4":2185,"NA":2191},{"trials":2178,"activeCount":100},[],{"trials":2180,"activeCount":100},[],{"trials":2182,"activeCount":100},[],{"trials":2184,"activeCount":100},[],{"trials":2186,"activeCount":100},[2187],{"nctId":2160,"briefTitle":2161,"status":448,"phases":2188,"primaryCompletion":2163,"completion":2164,"start":2165,"enrollment":2166,"conditions":2189,"interventions":2190},[91],[2168,2169,2170],[2147,2172],{"trials":2192,"activeCount":100},[],{"intervention":2194,"totalTrials":96,"cells":2195},"scopolamine patch",{"EARLY_PHASE1":2196,"PHASE1":2198,"PHASE2":2200,"PHASE3":2202,"PHASE4":2204,"NA":2215},{"trials":2197,"activeCount":100},[],{"trials":2199,"activeCount":100},[],{"trials":2201,"activeCount":100},[],{"trials":2203,"activeCount":100},[],{"trials":2205,"activeCount":100},[2206],{"nctId":2207,"briefTitle":2208,"status":448,"phases":2209,"primaryCompletion":2210,"completion":2210,"start":2211,"enrollment":2212,"conditions":2213,"interventions":2214},"NCT02960113","Scopolamine Patch and Acupressure Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean Section",[91],"2021-09","2016-05",240,[2168,2169,2170],[2194],{"trials":2216,"activeCount":100},[],{"intervention":2218,"totalTrials":96,"cells":2219},"Nicotine Nasal Spray",{"EARLY_PHASE1":2220,"PHASE1":2222,"PHASE2":2224,"PHASE3":2226,"PHASE4":2228,"NA":2242},{"trials":2221,"activeCount":100},[],{"trials":2223,"activeCount":100},[],{"trials":2225,"activeCount":100},[],{"trials":2227,"activeCount":100},[],{"trials":2229,"activeCount":100},[2230],{"nctId":2231,"briefTitle":2232,"status":448,"phases":2233,"primaryCompletion":2234,"completion":2235,"start":2236,"enrollment":2237,"conditions":2238,"interventions":2241},"NCT01010477","Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia",[91],"2012-07","2012-08","2009-08",66,[2239,2240],"Smoking Cessation","Schizophrenia",[2218],{"trials":2243,"activeCount":100},[],{"intervention":2245,"totalTrials":96,"cells":2246},"Gapabentin",{"EARLY_PHASE1":2247,"PHASE1":2249,"PHASE2":2251,"PHASE3":2253,"PHASE4":2255,"NA":2267},{"trials":2248,"activeCount":100},[],{"trials":2250,"activeCount":100},[],{"trials":2252,"activeCount":100},[],{"trials":2254,"activeCount":100},[],{"trials":2256,"activeCount":100},[2257],{"nctId":2258,"briefTitle":2259,"status":463,"phases":2260,"primaryCompletion":2261,"completion":2262,"start":2263,"enrollment":467,"conditions":2264,"interventions":2266},"NCT01546857","Effect of Gabapentin on Orthopedic Pain",[91],"2016-01","2016-12","2012-03",[2265],"Degenerative Arthritis and Postoperative Pain",[2245],{"trials":2268,"activeCount":100},[],{"intervention":2270,"totalTrials":96,"cells":2271},"Povidone-Iodine 10%",{"EARLY_PHASE1":2272,"PHASE1":2274,"PHASE2":2276,"PHASE3":2278,"PHASE4":2280,"NA":2296},{"trials":2273,"activeCount":100},[],{"trials":2275,"activeCount":100},[],{"trials":2277,"activeCount":100},[],{"trials":2279,"activeCount":100},[],{"trials":2281,"activeCount":100},[2282],{"nctId":2283,"briefTitle":2284,"status":448,"phases":2285,"primaryCompletion":2286,"completion":2287,"start":2288,"enrollment":2289,"conditions":2290,"interventions":2294},"NCT05529173","Povidone-Iodine for Nasal Decolonization",[91],"2023-11-13","2023-11-17","2022-09-06",192,[2291,2292,2293],"Surgical Wound Infection","Preoperative Care","Methicillin-Resistant Staphylococcus Aureus",[2270,2295],"0.9% NaCl Solution",{"trials":2297,"activeCount":100},[],{"intervention":2295,"totalTrials":96,"cells":2299},{"EARLY_PHASE1":2300,"PHASE1":2302,"PHASE2":2304,"PHASE3":2306,"PHASE4":2308,"NA":2314},{"trials":2301,"activeCount":100},[],{"trials":2303,"activeCount":100},[],{"trials":2305,"activeCount":100},[],{"trials":2307,"activeCount":100},[],{"trials":2309,"activeCount":100},[2310],{"nctId":2283,"briefTitle":2284,"status":448,"phases":2311,"primaryCompletion":2286,"completion":2287,"start":2288,"enrollment":2289,"conditions":2312,"interventions":2313},[91],[2291,2292,2293],[2270,2295],{"trials":2315,"activeCount":100},[],{"intervention":2317,"totalTrials":96,"cells":2318},"Nicotine Replacement Therapy Sampling",{"EARLY_PHASE1":2319,"PHASE1":2321,"PHASE2":2323,"PHASE3":2325,"PHASE4":2327,"NA":2339},{"trials":2320,"activeCount":100},[],{"trials":2322,"activeCount":100},[],{"trials":2324,"activeCount":100},[],{"trials":2326,"activeCount":100},[],{"trials":2328,"activeCount":100},[2329],{"nctId":2330,"briefTitle":2331,"status":448,"phases":2332,"primaryCompletion":2333,"completion":2333,"start":2334,"enrollment":2335,"conditions":2336,"interventions":2338},"NCT03620708","Tobacco and Socioeconomic Disadvantage",[91],"2018-10-01","2018-05-30",58,[2337],"Tobacco Smoking",[2317],{"trials":2340,"activeCount":100},[],{"intervention":2342,"totalTrials":96,"cells":2343},"Dexmedetomidine",{"EARLY_PHASE1":2344,"PHASE1":2346,"PHASE2":2348,"PHASE3":2350,"PHASE4":2352,"NA":2366},{"trials":2345,"activeCount":100},[],{"trials":2347,"activeCount":100},[],{"trials":2349,"activeCount":100},[],{"trials":2351,"activeCount":100},[],{"trials":2353,"activeCount":100},[2354],{"nctId":2355,"briefTitle":2356,"status":448,"phases":2357,"primaryCompletion":2358,"completion":2359,"start":2360,"enrollment":2361,"conditions":2362,"interventions":2364},"NCT01001429","Dexmedetomidine Versus Propofol in Vitreoretinal Surgery",[91],"2013-03","2013-11","2009-10",78,[2363],"Retinal Detachment",[2342,2365],"propofol",{"trials":2367,"activeCount":100},[],{"intervention":2369,"totalTrials":705,"cells":2370},"Red Blood Cell Transfusion",{"EARLY_PHASE1":2371,"PHASE1":2373,"PHASE2":2375,"PHASE3":2377,"PHASE4":2403,"NA":2405},{"trials":2372,"activeCount":100},[],{"trials":2374,"activeCount":100},[],{"trials":2376,"activeCount":100},[],{"trials":2378,"activeCount":100},[2379,2391],{"nctId":2380,"briefTitle":2381,"status":448,"phases":2382,"primaryCompletion":2383,"completion":2384,"start":2385,"enrollment":2386,"conditions":2387,"interventions":2390},"NCT02981407","Myocardial Ischemia and Transfusion",[90],"2023-05-31","2023-10-20","2017-04-25",3506,[2388,2389],"Myocardial Infarction","Anemia",[2369],{"nctId":2392,"briefTitle":2393,"status":448,"phases":2394,"primaryCompletion":2395,"completion":2395,"start":2396,"enrollment":2397,"conditions":2398,"interventions":2401},"NCT01167582","Myocardial Ischemia and Transfusion Pilot",[90],"2012-06","2009-09",110,[2388,2399,2400],"Unstable Angina","Coronary Artery Disease",[2402],"Red blood cell transfusion",{"trials":2404,"activeCount":100},[],{"trials":2406,"activeCount":100},[],{"intervention":2408,"totalTrials":96,"cells":2409},"Dipyridamole ER 200mg\u002F Aspirin 25mg orally\u002Fenterally AND Standard of care",{"EARLY_PHASE1":2410,"PHASE1":2412,"PHASE2":2414,"PHASE3":2416,"PHASE4":2428,"NA":2430},{"trials":2411,"activeCount":100},[],{"trials":2413,"activeCount":100},[],{"trials":2415,"activeCount":100},[],{"trials":2417,"activeCount":100},[2418],{"nctId":2419,"briefTitle":2420,"status":448,"phases":2421,"primaryCompletion":2422,"completion":2422,"start":2423,"enrollment":2424,"conditions":2425,"interventions":2427},"NCT04410328","Aggrenox To Treat Acute Covid-19",[90],"2021-10-15","2020-10-21",98,[2426],"Covid19",[2408],{"trials":2429,"activeCount":100},[],{"trials":2431,"activeCount":100},[],{"intervention":2433,"totalTrials":96,"cells":2434},"Triamcinolone",{"EARLY_PHASE1":2435,"PHASE1":2437,"PHASE2":2439,"PHASE3":2441,"PHASE4":2452,"NA":2454},{"trials":2436,"activeCount":100},[],{"trials":2438,"activeCount":100},[],{"trials":2440,"activeCount":100},[],{"trials":2442,"activeCount":100},[2443],{"nctId":2444,"briefTitle":2445,"status":463,"phases":2446,"primaryCompletion":2447,"completion":2447,"start":2139,"enrollment":2448,"conditions":2449,"interventions":2451},"NCT02191748","Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo",[89,90],"2018-01",22,[2450],"Vitiligo",[2433],{"trials":2453,"activeCount":100},[],{"trials":2455,"activeCount":100},[],{"intervention":2457,"totalTrials":96,"cells":2458},"Sphenopalatine Ganglion Block",{"EARLY_PHASE1":2459,"PHASE1":2461,"PHASE2":2463,"PHASE3":2465,"PHASE4":2475,"NA":2477},{"trials":2460,"activeCount":100},[],{"trials":2462,"activeCount":100},[],{"trials":2464,"activeCount":100},[],{"trials":2466,"activeCount":100},[2467],{"nctId":2468,"briefTitle":2469,"status":463,"phases":2470,"primaryCompletion":2471,"completion":2471,"start":1970,"enrollment":28,"conditions":2472,"interventions":2474},"NCT03112720","Therapeutic Epidural Patch Versus Pain Block in the Midface for Headache",[90],"2020-09",[2473],"Postdural Puncture Headache",[2457],{"trials":2476,"activeCount":100},[],{"trials":2478,"activeCount":100},[],{"intervention":2480,"totalTrials":96,"cells":2481},"Early Radiation Oncology Involvement Alongside Standard Oncologic Care",{"EARLY_PHASE1":2482,"PHASE1":2484,"PHASE2":2486,"PHASE3":2488,"PHASE4":2502,"NA":2504},{"trials":2483,"activeCount":100},[],{"trials":2485,"activeCount":100},[],{"trials":2487,"activeCount":100},[],{"trials":2489,"activeCount":100},[2490],{"nctId":2491,"briefTitle":2492,"status":2493,"phases":2494,"primaryCompletion":2495,"completion":2496,"start":2497,"enrollment":2498,"conditions":2499,"interventions":2501},"NCT05351294","Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet","SUSPENDED",[90],"2026-12-30","2027-12-30","2023-07-13",156,[1499,2500],"Metastatic Cancer",[2480],{"trials":2503,"activeCount":100},[],{"trials":2505,"activeCount":100},[],{"intervention":2507,"totalTrials":96,"cells":2508},"OPIOID",{"EARLY_PHASE1":2509,"PHASE1":2511,"PHASE2":2513,"PHASE3":2515,"PHASE4":2528,"NA":2530},{"trials":2510,"activeCount":100},[],{"trials":2512,"activeCount":100},[],{"trials":2514,"activeCount":100},[],{"trials":2516,"activeCount":100},[2517],{"nctId":2518,"briefTitle":2519,"status":448,"phases":2520,"primaryCompletion":2521,"completion":2522,"start":2523,"enrollment":2524,"conditions":2525,"interventions":2526},"NCT05283499","Opioid Analgesic Reduction Study (OARS) - Pilot",[90],"2021-03-12","2021-03-26","2020-07-06",53,[213],[2507,2527],"NON-OPIOID",{"trials":2529,"activeCount":100},[],{"trials":2531,"activeCount":100},[],{"intervention":2527,"totalTrials":96,"cells":2533},{"EARLY_PHASE1":2534,"PHASE1":2536,"PHASE2":2538,"PHASE3":2540,"PHASE4":2546,"NA":2548},{"trials":2535,"activeCount":100},[],{"trials":2537,"activeCount":100},[],{"trials":2539,"activeCount":100},[],{"trials":2541,"activeCount":100},[2542],{"nctId":2518,"briefTitle":2519,"status":448,"phases":2543,"primaryCompletion":2521,"completion":2522,"start":2523,"enrollment":2524,"conditions":2544,"interventions":2545},[90],[213],[2507,2527],{"trials":2547,"activeCount":100},[],{"trials":2549,"activeCount":100},[],{"intervention":2551,"totalTrials":96,"cells":2552},"Amoxicillin",{"EARLY_PHASE1":2553,"PHASE1":2555,"PHASE2":2557,"PHASE3":2559,"PHASE4":2574,"NA":2576},{"trials":2554,"activeCount":100},[],{"trials":2556,"activeCount":100},[],{"trials":2558,"activeCount":100},[],{"trials":2560,"activeCount":100},[2561],{"nctId":2562,"briefTitle":2563,"status":448,"phases":2564,"primaryCompletion":2565,"completion":2565,"start":2566,"enrollment":2567,"conditions":2568,"interventions":2572},"NCT06131021","Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice",[90],"2026-04-07","2024-04-25",236,[2569,2570,2571],"Periodontitis","Periodontal Diseases","Periodontal Pocket",[2551,2573],"Metronidazole",{"trials":2575,"activeCount":100},[],{"trials":2577,"activeCount":100},[],{"intervention":2573,"totalTrials":96,"cells":2579},{"EARLY_PHASE1":2580,"PHASE1":2582,"PHASE2":2584,"PHASE3":2586,"PHASE4":2592,"NA":2594},{"trials":2581,"activeCount":100},[],{"trials":2583,"activeCount":100},[],{"trials":2585,"activeCount":100},[],{"trials":2587,"activeCount":100},[2588],{"nctId":2562,"briefTitle":2563,"status":448,"phases":2589,"primaryCompletion":2565,"completion":2565,"start":2566,"enrollment":2567,"conditions":2590,"interventions":2591},[90],[2569,2570,2571],[2551,2573],{"trials":2593,"activeCount":100},[],{"trials":2595,"activeCount":100},[],{"intervention":2597,"totalTrials":96,"cells":2598},"Liberal (10 g\u002FdL) Transfusion Strategy",{"EARLY_PHASE1":2599,"PHASE1":2601,"PHASE2":2603,"PHASE3":2605,"PHASE4":2622,"NA":2624},{"trials":2600,"activeCount":100},[],{"trials":2602,"activeCount":100},[],{"trials":2604,"activeCount":100},[],{"trials":2606,"activeCount":100},[2607],{"nctId":2608,"briefTitle":2609,"status":448,"phases":2610,"primaryCompletion":2611,"completion":2611,"start":2612,"enrollment":2613,"conditions":2614,"interventions":2620},"NCT00071032","Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease",[90],"2009-05","2003-07",2016,[2389,2615,2616,369,2388,2617,2618,2619],"Hematologic Diseases","Cardiovascular Diseases","Thromboembolism","Pneumonia","Cerebrovascular Accident",[2597,2621],"Restrictive (Symptomatic) Transfusion Strategy",{"trials":2623,"activeCount":100},[],{"trials":2625,"activeCount":100},[],{"intervention":2621,"totalTrials":96,"cells":2627},{"EARLY_PHASE1":2628,"PHASE1":2630,"PHASE2":2632,"PHASE3":2634,"PHASE4":2640,"NA":2642},{"trials":2629,"activeCount":100},[],{"trials":2631,"activeCount":100},[],{"trials":2633,"activeCount":100},[],{"trials":2635,"activeCount":100},[2636],{"nctId":2608,"briefTitle":2609,"status":448,"phases":2637,"primaryCompletion":2611,"completion":2611,"start":2612,"enrollment":2613,"conditions":2638,"interventions":2639},[90],[2389,2615,2616,369,2388,2617,2618,2619],[2597,2621],{"trials":2641,"activeCount":100},[],{"trials":2643,"activeCount":100},[],{"intervention":2645,"totalTrials":96,"cells":2646},"Carvedilol",{"EARLY_PHASE1":2647,"PHASE1":2649,"PHASE2":2651,"PHASE3":2653,"PHASE4":2664,"NA":2666},{"trials":2648,"activeCount":100},[],{"trials":2650,"activeCount":100},[],{"trials":2652,"activeCount":100},[],{"trials":2654,"activeCount":100},[2655],{"nctId":2656,"briefTitle":2657,"status":1899,"phases":2658,"primaryCompletion":2659,"completion":2210,"start":2660,"enrollment":100,"conditions":2661,"interventions":2663},"NCT02066649","Carvedilol vs Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding",[90],"2019-03","2018-07",[2662],"Portal Hypertension Related to Cirrhosis",[2645],{"trials":2665,"activeCount":100},[],{"trials":2667,"activeCount":100},[],{"intervention":2669,"totalTrials":96,"cells":2670},"Fresh frozen plasma transfusion",{"EARLY_PHASE1":2671,"PHASE1":2673,"PHASE2":2675,"PHASE3":2677,"PHASE4":2690,"NA":2692},{"trials":2672,"activeCount":100},[],{"trials":2674,"activeCount":100},[],{"trials":2676,"activeCount":100},[],{"trials":2678,"activeCount":100},[2679],{"nctId":2680,"briefTitle":2681,"status":448,"phases":2682,"primaryCompletion":2683,"completion":2684,"start":2685,"enrollment":1874,"conditions":2686,"interventions":2689},"NCT02637427","Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures",[90],"2019-06-28","2020-11","2016-02-26",[2687,2688],"Blood Coagulation Disorders","Hemorrhage",[2669],{"trials":2691,"activeCount":100},[],{"trials":2693,"activeCount":100},[],{"intervention":487,"totalTrials":35,"cells":2695},{"EARLY_PHASE1":2696,"PHASE1":2716,"PHASE2":2718,"PHASE3":2763,"PHASE4":2765,"NA":2767},{"trials":2697,"activeCount":100},[2698,2706],{"nctId":2699,"briefTitle":2700,"status":463,"phases":2701,"primaryCompletion":2685,"completion":2685,"start":2234,"enrollment":2702,"conditions":2703,"interventions":2705},"NCT02421575","Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance",[87],4,[2704],"Prostate Carcinoma",[487],{"nctId":2707,"briefTitle":2708,"status":448,"phases":2709,"primaryCompletion":2710,"completion":2710,"start":2711,"enrollment":9,"conditions":2712,"interventions":2714},"NCT00962845","Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery",[87],"2013-05-30","2010-09",[2713],"Melanoma (Skin)",[2715],"hydroxychloroquine",{"trials":2717,"activeCount":100},[],{"trials":2719,"activeCount":100},[2720,2729,2739,2751,2755],{"nctId":2721,"briefTitle":2722,"status":448,"phases":2723,"primaryCompletion":2724,"completion":2725,"start":2611,"enrollment":1406,"conditions":2726,"interventions":2728},"NCT01006369","Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",[89],"2015-08-06","2016-04-27",[2727],"Colorectal Cancer",[2715],{"nctId":2730,"briefTitle":2731,"status":463,"phases":2732,"primaryCompletion":1028,"completion":2733,"start":2734,"enrollment":19,"conditions":2735,"interventions":2736},"NCT01828476","Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer",[89],"2016-03-03","2013-06",[18],[2737,2738,487],"Abiraterone","ABT-263",{"nctId":2740,"briefTitle":2741,"status":463,"phases":2742,"primaryCompletion":2743,"completion":2744,"start":2745,"enrollment":35,"conditions":2746,"interventions":2748},"NCT04605588","A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19",[89],"2021-01-17","2021-02-04","2020-12-02",[2747,2426],"SARS-CoV Infection",[2749,2750,487],"Nitazoxanide","Ribavirin",{"nctId":476,"briefTitle":477,"status":448,"phases":2752,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":2753,"interventions":2754},[89],[483,484,485],[459,439,487,488],{"nctId":2756,"briefTitle":2757,"status":448,"phases":2758,"primaryCompletion":1858,"completion":2447,"start":2759,"enrollment":2760,"conditions":2761,"interventions":2762},"NCT00726596","Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer",[89],"2008-08",64,[18],[2715],{"trials":2764,"activeCount":100},[],{"trials":2766,"activeCount":100},[],{"trials":2768,"activeCount":100},[],{"intervention":2770,"totalTrials":546,"cells":2771},"gemcitabine hydrochloride",{"EARLY_PHASE1":2772,"PHASE1":2774,"PHASE2":2786,"PHASE3":2808,"PHASE4":2810,"NA":2812},{"trials":2773,"activeCount":100},[],{"trials":2775,"activeCount":100},[2776],{"nctId":2777,"briefTitle":2778,"status":463,"phases":2779,"primaryCompletion":2780,"completion":2781,"start":2782,"enrollment":28,"conditions":2783,"interventions":2785},"NCT00878657","Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer",[88],"2012-10","2013-10","2009-04",[2784],"Pancreatic Cancer",[2770],{"trials":2787,"activeCount":100},[2788,2799],{"nctId":2789,"briefTitle":2790,"status":463,"phases":2791,"primaryCompletion":2792,"completion":2793,"start":2794,"enrollment":2795,"conditions":2796,"interventions":2797},"NCT00323063","Gemcitabine +\u002F- Imatinib Mesylate, Patients w\u002FPreviously Treated Metastatic Breast Cancer",[89],"2011-04-15","2016-06-20","2006-05-01",49,[15],[2770,2798],"imatinib mesylate",{"nctId":2800,"briefTitle":2801,"status":463,"phases":2802,"primaryCompletion":2803,"completion":2803,"start":2804,"enrollment":2805,"conditions":2806,"interventions":2807},"NCT00323362","Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer",[89],"2008-10","2006-04",17,[530],[2770,2798],{"trials":2809,"activeCount":100},[],{"trials":2811,"activeCount":100},[],{"trials":2813,"activeCount":100},[],{"intervention":2815,"totalTrials":546,"cells":2816},"cyclophosphamide",{"EARLY_PHASE1":2817,"PHASE1":2819,"PHASE2":2821,"PHASE3":2863,"PHASE4":2865,"NA":2867},{"trials":2818,"activeCount":100},[],{"trials":2820,"activeCount":100},[],{"trials":2822,"activeCount":100},[2823,2834,2854],{"nctId":2824,"briefTitle":2825,"status":1968,"phases":2826,"primaryCompletion":1858,"completion":2827,"start":1873,"enrollment":495,"conditions":2828,"interventions":2832},"NCT00553683","Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer",[88,89],"2014-07",[15,2727,2829,2830,2713,2500,2831,2784],"Gastric Cancer","Liver Cancer","Ovarian Cancer",[2815,2833],"poly ICLC",{"nctId":2835,"briefTitle":2836,"status":448,"phases":2837,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":1431,"conditions":2840,"interventions":2842},"NCT00176462","CINJALL: Treatment for Children With Acute Lymphocytic Leukemia",[89],"2008-09","2001-02",[2841],"Acute Lymphocytic Leukemia",[2843,2844,2815,2845,2846,2847,2848,2849,2850,2851,2852,2853],"aminopterin","L-asparaginase","cytarabine","daunomycin","dexamethasone","6-mercaptopurine","methotrexate","6-thioguanine","vincristine","Triple Intrathecal Therapy","Leucovorin",{"nctId":2855,"briefTitle":2856,"status":448,"phases":2857,"primaryCompletion":2803,"completion":2803,"start":2858,"enrollment":16,"conditions":2859,"interventions":2860},"NCT00176605","Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer",[89],"2005-05",[18],[2861,2862],"Etoposide","Cyclophosphamide",{"trials":2864,"activeCount":100},[],{"trials":2866,"activeCount":100},[],{"trials":2868,"activeCount":100},[],{"intervention":2870,"totalTrials":546,"cells":2871},"choline magnesium trisalicylate",{"EARLY_PHASE1":2872,"PHASE1":2874,"PHASE2":2886,"PHASE3":2925,"PHASE4":2927,"NA":2929},{"trials":2873,"activeCount":100},[],{"trials":2875,"activeCount":100},[2876],{"nctId":2877,"briefTitle":2878,"status":463,"phases":2879,"primaryCompletion":2880,"completion":2880,"start":2881,"enrollment":16,"conditions":2882,"interventions":2884},"NCT00156299","Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate",[88],"2008-07","2003-03",[2883],"Leukemia",[2870,2885],"Dexamethasone",{"trials":2887,"activeCount":100},[2888,2915],{"nctId":2889,"briefTitle":2890,"status":448,"phases":2891,"primaryCompletion":2892,"completion":2892,"start":2893,"enrollment":2894,"conditions":2895,"interventions":2913},"NCT02144675","Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia",[89],"2016-04-26","2009-01",27,[2896,2897,2898,2899,2900,2901,2902,2903,2904,2905,2906,2907,2908,2909,2910,2911,2912],"Adult Acute Megakaryoblastic Leukemia (M7)","Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","Adult Acute Monoblastic Leukemia (M5a)","Adult Acute Monocytic Leukemia (M5b)","Adult Acute Myeloblastic Leukemia With Maturation (M2)","Adult Acute Myeloblastic Leukemia Without Maturation (M1)","Adult Acute Myeloid Leukemia in Remission","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","Adult Acute Myelomonocytic Leukemia (M4)","Adult Erythroleukemia (M6a)","Adult Pure Erythroid Leukemia (M6b)","Recurrent Adult Acute Myeloid Leukemia","Untreated Adult Acute Myeloid Leukemia",[2870,2914,2845],"idarubicin",{"nctId":2916,"briefTitle":2917,"status":463,"phases":2918,"primaryCompletion":2919,"completion":2139,"start":2920,"enrollment":96,"conditions":2921,"interventions":2922},"NCT01009931","Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies",[89],"2011-10","2011-03",[2883],[2923,2885,2924],"12-O-tetradecanoylphorbol-13-acetate","Choline magnesium trisalicylate",{"trials":2926,"activeCount":100},[],{"trials":2928,"activeCount":100},[],{"trials":2930,"activeCount":100},[],{"intervention":2885,"totalTrials":546,"cells":2932},{"EARLY_PHASE1":2933,"PHASE1":2935,"PHASE2":2941,"PHASE3":2951,"PHASE4":2953,"NA":2955},{"trials":2934,"activeCount":100},[],{"trials":2936,"activeCount":100},[2937],{"nctId":2877,"briefTitle":2878,"status":463,"phases":2938,"primaryCompletion":2880,"completion":2880,"start":2881,"enrollment":16,"conditions":2939,"interventions":2940},[88],[2883],[2870,2885],{"trials":2942,"activeCount":100},[2943,2947],{"nctId":2835,"briefTitle":2836,"status":448,"phases":2944,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":1431,"conditions":2945,"interventions":2946},[89],[2841],[2843,2844,2815,2845,2846,2847,2848,2849,2850,2851,2852,2853],{"nctId":2916,"briefTitle":2917,"status":463,"phases":2948,"primaryCompletion":2919,"completion":2139,"start":2920,"enrollment":96,"conditions":2949,"interventions":2950},[89],[2883],[2923,2885,2924],{"trials":2952,"activeCount":100},[],{"trials":2954,"activeCount":100},[],{"trials":2956,"activeCount":100},[],{"intervention":2958,"totalTrials":705,"cells":2959},"therapeutic allogeneic lymphocytes",{"EARLY_PHASE1":2960,"PHASE1":2962,"PHASE2":2964,"PHASE3":2983,"PHASE4":2985,"NA":2987},{"trials":2961,"activeCount":100},[],{"trials":2963,"activeCount":100},[],{"trials":2965,"activeCount":100},[2966,2974],{"nctId":2967,"briefTitle":2968,"status":463,"phases":2969,"primaryCompletion":2759,"completion":2759,"start":2970,"enrollment":546,"conditions":2971,"interventions":2973},"NCT00176501","Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer",[89],"2004-08",[2972],"Kidney Cancer",[2958],{"nctId":2975,"briefTitle":2976,"status":463,"phases":2977,"primaryCompletion":2978,"completion":2978,"start":2979,"enrollment":22,"conditions":2980,"interventions":2981},"NCT00853125","Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer",[89],"2014-02-22","2009-02",[2972],[2958,2982],"sunitinib malate",{"trials":2984,"activeCount":100},[],{"trials":2986,"activeCount":100},[],{"trials":2988,"activeCount":100},[],{"intervention":2798,"totalTrials":705,"cells":2990},{"EARLY_PHASE1":2991,"PHASE1":2993,"PHASE2":2995,"PHASE3":3005,"PHASE4":3007,"NA":3009},{"trials":2992,"activeCount":100},[],{"trials":2994,"activeCount":100},[],{"trials":2996,"activeCount":100},[2997,3001],{"nctId":2789,"briefTitle":2790,"status":463,"phases":2998,"primaryCompletion":2792,"completion":2793,"start":2794,"enrollment":2795,"conditions":2999,"interventions":3000},[89],[15],[2770,2798],{"nctId":2800,"briefTitle":2801,"status":463,"phases":3002,"primaryCompletion":2803,"completion":2803,"start":2804,"enrollment":2805,"conditions":3003,"interventions":3004},[89],[530],[2770,2798],{"trials":3006,"activeCount":100},[],{"trials":3008,"activeCount":100},[],{"trials":3010,"activeCount":100},[],{"intervention":3012,"totalTrials":705,"cells":3013},"riluzole",{"EARLY_PHASE1":3014,"PHASE1":3016,"PHASE2":3027,"PHASE3":3036,"PHASE4":3038,"NA":3040},{"trials":3015,"activeCount":100},[],{"trials":3017,"activeCount":100},[3018],{"nctId":3019,"briefTitle":3020,"status":463,"phases":3021,"primaryCompletion":3022,"completion":3022,"start":3023,"enrollment":25,"conditions":3024,"interventions":3026},"NCT01018836","Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases",[88],"2013-12","2009-11",[2500,3025],"Unspecified Adult Solid Tumor, Protocol Specific",[3012],{"trials":3028,"activeCount":100},[3029],{"nctId":3030,"briefTitle":3031,"status":448,"phases":3032,"primaryCompletion":3033,"completion":3033,"start":2782,"enrollment":19,"conditions":3034,"interventions":3035},"NCT00866840","Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery",[89],"2013-07",[2713],[3012],{"trials":3037,"activeCount":100},[],{"trials":3039,"activeCount":100},[],{"trials":3041,"activeCount":100},[],{"intervention":3043,"totalTrials":705,"cells":3044},"Venetoclax",{"EARLY_PHASE1":3045,"PHASE1":3047,"PHASE2":3049,"PHASE3":3087,"PHASE4":3089,"NA":3091},{"trials":3046,"activeCount":100},[],{"trials":3048,"activeCount":100},[],{"trials":3050,"activeCount":100},[3051,3071],{"nctId":3052,"briefTitle":3053,"status":448,"phases":3054,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":677,"conditions":3058,"interventions":3067},"NCT04146038","Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia\u002FMyeloproliferative Disease",[89],"2021-10-25","2022-10-25","2020-10-26",[3059,3060,3061,3062,3063,3064,3065,3066],"Acute Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells","Myelodysplastic Syndrome","Myeloproliferative Neoplasm","Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia","Secondary Acute Myeloid Leukemia",[3068,3069,3070,3043],"Azacitidine","Decitabine","Salsalate",{"nctId":3072,"briefTitle":3073,"status":1899,"phases":3074,"primaryCompletion":2114,"completion":2114,"start":3075,"enrollment":100,"conditions":3076,"interventions":3084},"NCT04285268","Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[89],"2020-05-06",[3077,3078,3079,3080,3081,3082,3083],"High Grade B-Cell Lymphoma, Not Otherwise Specified","Recurrent Burkitt Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory Burkitt Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",[3085,3086,3043],"Bortezomib","Rituximab",{"trials":3088,"activeCount":100},[],{"trials":3090,"activeCount":100},[],{"trials":3092,"activeCount":100},[],{"intervention":488,"totalTrials":705,"cells":3094},{"EARLY_PHASE1":3095,"PHASE1":3097,"PHASE2":3099,"PHASE3":3109,"PHASE4":3111,"NA":3113},{"trials":3096,"activeCount":100},[],{"trials":3098,"activeCount":100},[],{"trials":3100,"activeCount":100},[3101,3105],{"nctId":476,"briefTitle":477,"status":448,"phases":3102,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":3103,"interventions":3104},[89],[483,484,485],[459,439,487,488],{"nctId":535,"briefTitle":536,"status":448,"phases":3106,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":3107,"interventions":3108},[89],[543],[545,439,488],{"trials":3110,"activeCount":100},[],{"trials":3112,"activeCount":100},[],{"trials":3114,"activeCount":100},[],{"intervention":3116,"totalTrials":96,"cells":3117},"Aspirin",{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3122,"PHASE3":3138,"PHASE4":3140,"NA":3142},{"trials":3119,"activeCount":100},[],{"trials":3121,"activeCount":100},[],{"trials":3123,"activeCount":100},[3124],{"nctId":3125,"briefTitle":3126,"status":463,"phases":3127,"primaryCompletion":3128,"completion":3128,"start":3129,"enrollment":2894,"conditions":3130,"interventions":3136},"NCT02420652","Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy",[89],"2019-12-01","2015-06-23",[3131,3132,3133,3134,3135],"Recurrent Prostate Carcinoma","Stage I Prostate Cancer","Stage IIA Prostate Cancer","Stage IIB Prostate Cancer","Stage III Prostate Cancer",[3116,3137],"Metformin Hydrochloride",{"trials":3139,"activeCount":100},[],{"trials":3141,"activeCount":100},[],{"trials":3143,"activeCount":100},[],{"intervention":3137,"totalTrials":96,"cells":3145},{"EARLY_PHASE1":3146,"PHASE1":3148,"PHASE2":3150,"PHASE3":3156,"PHASE4":3158,"NA":3160},{"trials":3147,"activeCount":100},[],{"trials":3149,"activeCount":100},[],{"trials":3151,"activeCount":100},[3152],{"nctId":3125,"briefTitle":3126,"status":463,"phases":3153,"primaryCompletion":3128,"completion":3128,"start":3129,"enrollment":2894,"conditions":3154,"interventions":3155},[89],[3131,3132,3133,3134,3135],[3116,3137],{"trials":3157,"activeCount":100},[],{"trials":3159,"activeCount":100},[],{"trials":3161,"activeCount":100},[],{"intervention":3163,"totalTrials":96,"cells":3164},"atorvastatin calcium",{"EARLY_PHASE1":3165,"PHASE1":3167,"PHASE2":3169,"PHASE3":3179,"PHASE4":3181,"NA":3183},{"trials":3166,"activeCount":100},[],{"trials":3168,"activeCount":100},[],{"trials":3170,"activeCount":100},[3171],{"nctId":3172,"briefTitle":3173,"status":448,"phases":3174,"primaryCompletion":3175,"completion":3175,"start":2979,"enrollment":2894,"conditions":3176,"interventions":3177},"NCT01220973","Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer",[89],"2014-11-18",[18],[3163,3178],"celecoxib",{"trials":3180,"activeCount":100},[],{"trials":3182,"activeCount":100},[],{"trials":3184,"activeCount":100},[],{"intervention":3178,"totalTrials":96,"cells":3186},{"EARLY_PHASE1":3187,"PHASE1":3189,"PHASE2":3191,"PHASE3":3197,"PHASE4":3199,"NA":3201},{"trials":3188,"activeCount":100},[],{"trials":3190,"activeCount":100},[],{"trials":3192,"activeCount":100},[3193],{"nctId":3172,"briefTitle":3173,"status":448,"phases":3194,"primaryCompletion":3175,"completion":3175,"start":2979,"enrollment":2894,"conditions":3195,"interventions":3196},[89],[18],[3163,3178],{"trials":3198,"activeCount":100},[],{"trials":3200,"activeCount":100},[],{"trials":3202,"activeCount":100},[],{"intervention":2737,"totalTrials":96,"cells":3204},{"EARLY_PHASE1":3205,"PHASE1":3207,"PHASE2":3209,"PHASE3":3215,"PHASE4":3217,"NA":3219},{"trials":3206,"activeCount":100},[],{"trials":3208,"activeCount":100},[],{"trials":3210,"activeCount":100},[3211],{"nctId":2730,"briefTitle":2731,"status":463,"phases":3212,"primaryCompletion":1028,"completion":2733,"start":2734,"enrollment":19,"conditions":3213,"interventions":3214},[89],[18],[2737,2738,487],{"trials":3216,"activeCount":100},[],{"trials":3218,"activeCount":100},[],{"trials":3220,"activeCount":100},[],{"intervention":2738,"totalTrials":96,"cells":3222},{"EARLY_PHASE1":3223,"PHASE1":3225,"PHASE2":3227,"PHASE3":3233,"PHASE4":3235,"NA":3237},{"trials":3224,"activeCount":100},[],{"trials":3226,"activeCount":100},[],{"trials":3228,"activeCount":100},[3229],{"nctId":2730,"briefTitle":2731,"status":463,"phases":3230,"primaryCompletion":1028,"completion":2733,"start":2734,"enrollment":19,"conditions":3231,"interventions":3232},[89],[18],[2737,2738,487],{"trials":3234,"activeCount":100},[],{"trials":3236,"activeCount":100},[],{"trials":3238,"activeCount":100},[],{"intervention":2833,"totalTrials":96,"cells":3240},{"EARLY_PHASE1":3241,"PHASE1":3243,"PHASE2":3245,"PHASE3":3251,"PHASE4":3253,"NA":3255},{"trials":3242,"activeCount":100},[],{"trials":3244,"activeCount":100},[],{"trials":3246,"activeCount":100},[3247],{"nctId":2824,"briefTitle":2825,"status":1968,"phases":3248,"primaryCompletion":1858,"completion":2827,"start":1873,"enrollment":495,"conditions":3249,"interventions":3250},[88,89],[15,2727,2829,2830,2713,2500,2831,2784],[2815,2833],{"trials":3252,"activeCount":100},[],{"trials":3254,"activeCount":100},[],{"trials":3256,"activeCount":100},[],{"intervention":3258,"totalTrials":96,"cells":3259},"combination of drugs",{"EARLY_PHASE1":3260,"PHASE1":3262,"PHASE2":3264,"PHASE3":3275,"PHASE4":3277,"NA":3279},{"trials":3261,"activeCount":100},[],{"trials":3263,"activeCount":100},[],{"trials":3265,"activeCount":100},[3266],{"nctId":3267,"briefTitle":3268,"status":2493,"phases":3269,"primaryCompletion":2496,"completion":3270,"start":3271,"enrollment":1406,"conditions":3272,"interventions":3274},"NCT05358704","Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer",[89],"2028-01-30","2022-05-13",[3273],"Cancer of Rectum",[3258],{"trials":3276,"activeCount":100},[],{"trials":3278,"activeCount":100},[],{"trials":3280,"activeCount":100},[],{"intervention":3282,"totalTrials":96,"cells":3283},"Gemcitabine and Capecitabine",{"EARLY_PHASE1":3284,"PHASE1":3286,"PHASE2":3288,"PHASE3":3298,"PHASE4":3300,"NA":3302},{"trials":3285,"activeCount":100},[],{"trials":3287,"activeCount":100},[],{"trials":3289,"activeCount":100},[3290],{"nctId":3291,"briefTitle":3292,"status":1899,"phases":3293,"primaryCompletion":3294,"completion":3294,"start":3295,"enrollment":100,"conditions":3296,"interventions":3297},"NCT05415917","Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy",[89],"2024-08-05","2022-07-29",[2784],[3282],{"trials":3299,"activeCount":100},[],{"trials":3301,"activeCount":100},[],{"trials":3303,"activeCount":100},[],{"intervention":3305,"totalTrials":96,"cells":3306},"68-Gallium citrate PET\u002FCT scan",{"EARLY_PHASE1":3307,"PHASE1":3309,"PHASE2":3311,"PHASE3":3323,"PHASE4":3325,"NA":3327},{"trials":3308,"activeCount":100},[],{"trials":3310,"activeCount":100},[],{"trials":3312,"activeCount":100},[3313],{"nctId":3314,"briefTitle":3315,"status":463,"phases":3316,"primaryCompletion":3317,"completion":3317,"start":3318,"enrollment":96,"conditions":3319,"interventions":3321},"NCT03123289","Novel Gallium 68 Citrate in Orthopedic Infections",[89],"2020-10-14","2017-03-06",[3320],"Joint Prosthesis",[3305,3322],"18F FDG PET\u002FCT scan",{"trials":3324,"activeCount":100},[],{"trials":3326,"activeCount":100},[],{"trials":3328,"activeCount":100},[],{"intervention":3322,"totalTrials":96,"cells":3330},{"EARLY_PHASE1":3331,"PHASE1":3333,"PHASE2":3335,"PHASE3":3341,"PHASE4":3343,"NA":3345},{"trials":3332,"activeCount":100},[],{"trials":3334,"activeCount":100},[],{"trials":3336,"activeCount":100},[3337],{"nctId":3314,"briefTitle":3315,"status":463,"phases":3338,"primaryCompletion":3317,"completion":3317,"start":3318,"enrollment":96,"conditions":3339,"interventions":3340},[89],[3320],[3305,3322],{"trials":3342,"activeCount":100},[],{"trials":3344,"activeCount":100},[],{"trials":3346,"activeCount":100},[],{"intervention":3348,"totalTrials":96,"cells":3349},"Heart Rate Variability Biofeedback",{"EARLY_PHASE1":3350,"PHASE1":3352,"PHASE2":3354,"PHASE3":3365,"PHASE4":3367,"NA":3369},{"trials":3351,"activeCount":100},[],{"trials":3353,"activeCount":100},[],{"trials":3355,"activeCount":100},[3356],{"nctId":3357,"briefTitle":3358,"status":448,"phases":3359,"primaryCompletion":3360,"completion":3360,"start":3361,"enrollment":913,"conditions":3362,"interventions":3363},"NCT05224050","Heart Rate Variability Biofeedback for Smoking Cessation Treatment",[89],"2023-06-15","2021-11-29",[2337],[3348,3364],"Nicotine patch",{"trials":3366,"activeCount":100},[],{"trials":3368,"activeCount":100},[],{"trials":3370,"activeCount":100},[],{"intervention":3372,"totalTrials":96,"cells":3373},"carrageenan-containing gel",{"EARLY_PHASE1":3374,"PHASE1":3376,"PHASE2":3378,"PHASE3":3390,"PHASE4":3392,"NA":3394},{"trials":3375,"activeCount":100},[],{"trials":3377,"activeCount":100},[],{"trials":3379,"activeCount":100},[3380],{"nctId":3381,"briefTitle":3382,"status":1899,"phases":3383,"primaryCompletion":3384,"completion":3384,"start":3385,"enrollment":100,"conditions":3386,"interventions":3389},"NCT02382419","Carrageenan-Containing Gel in Reducing the Rate of HPV Infection in Healthy Participants",[89],"2019-02-13","2016-02-24",[3387,3388],"Healthy Subject","Human Papillomavirus Infection",[3372],{"trials":3391,"activeCount":100},[],{"trials":3393,"activeCount":100},[],{"trials":3395,"activeCount":100},[],{"intervention":3397,"totalTrials":96,"cells":3398},"everolimus",{"EARLY_PHASE1":3399,"PHASE1":3401,"PHASE2":3403,"PHASE3":3415,"PHASE4":3417,"NA":3419},{"trials":3400,"activeCount":100},[],{"trials":3402,"activeCount":100},[],{"trials":3404,"activeCount":100},[3405],{"nctId":3406,"briefTitle":3407,"status":463,"phases":3408,"primaryCompletion":3409,"completion":3410,"start":3411,"enrollment":2894,"conditions":3412,"interventions":3413},"NCT00934895","Phase I\u002FII Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca",[88,89],"2014-01-07","2015-08-12","2009-07-15",[15],[3397,3414],"abraxane",{"trials":3416,"activeCount":100},[],{"trials":3418,"activeCount":100},[],{"trials":3420,"activeCount":100},[],{"intervention":3414,"totalTrials":96,"cells":3422},{"EARLY_PHASE1":3423,"PHASE1":3425,"PHASE2":3427,"PHASE3":3433,"PHASE4":3435,"NA":3437},{"trials":3424,"activeCount":100},[],{"trials":3426,"activeCount":100},[],{"trials":3428,"activeCount":100},[3429],{"nctId":3406,"briefTitle":3407,"status":463,"phases":3430,"primaryCompletion":3409,"completion":3410,"start":3411,"enrollment":2894,"conditions":3431,"interventions":3432},[88,89],[15],[3397,3414],{"trials":3434,"activeCount":100},[],{"trials":3436,"activeCount":100},[],{"trials":3438,"activeCount":100},[],{"intervention":3440,"totalTrials":96,"cells":3441},"Hydroxychloroquine sulfate &Azithromycin",{"EARLY_PHASE1":3442,"PHASE1":3444,"PHASE2":3446,"PHASE3":3457,"PHASE4":3459,"NA":3461},{"trials":3443,"activeCount":100},[],{"trials":3445,"activeCount":100},[],{"trials":3447,"activeCount":100},[3448],{"nctId":3449,"briefTitle":3450,"status":1899,"phases":3451,"primaryCompletion":2684,"completion":3452,"start":3453,"enrollment":100,"conditions":3454,"interventions":3456},"NCT04374552","Asymptomatic COVID-19 Trial",[89],"2021-04","2020-05-05",[3455],"SARS-CoV-2 Infection",[3440],{"trials":3458,"activeCount":100},[],{"trials":3460,"activeCount":100},[],{"trials":3462,"activeCount":100},[],{"intervention":2749,"totalTrials":96,"cells":3464},{"EARLY_PHASE1":3465,"PHASE1":3467,"PHASE2":3469,"PHASE3":3475,"PHASE4":3477,"NA":3479},{"trials":3466,"activeCount":100},[],{"trials":3468,"activeCount":100},[],{"trials":3470,"activeCount":100},[3471],{"nctId":2740,"briefTitle":2741,"status":463,"phases":3472,"primaryCompletion":2743,"completion":2744,"start":2745,"enrollment":35,"conditions":3473,"interventions":3474},[89],[2747,2426],[2749,2750,487],{"trials":3476,"activeCount":100},[],{"trials":3478,"activeCount":100},[],{"trials":3480,"activeCount":100},[],{"intervention":2750,"totalTrials":96,"cells":3482},{"EARLY_PHASE1":3483,"PHASE1":3485,"PHASE2":3487,"PHASE3":3493,"PHASE4":3495,"NA":3497},{"trials":3484,"activeCount":100},[],{"trials":3486,"activeCount":100},[],{"trials":3488,"activeCount":100},[3489],{"nctId":2740,"briefTitle":2741,"status":463,"phases":3490,"primaryCompletion":2743,"completion":2744,"start":2745,"enrollment":35,"conditions":3491,"interventions":3492},[89],[2747,2426],[2749,2750,487],{"trials":3494,"activeCount":100},[],{"trials":3496,"activeCount":100},[],{"trials":3498,"activeCount":100},[],{"intervention":3068,"totalTrials":96,"cells":3500},{"EARLY_PHASE1":3501,"PHASE1":3503,"PHASE2":3505,"PHASE3":3511,"PHASE4":3513,"NA":3515},{"trials":3502,"activeCount":100},[],{"trials":3504,"activeCount":100},[],{"trials":3506,"activeCount":100},[3507],{"nctId":3052,"briefTitle":3053,"status":448,"phases":3508,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":677,"conditions":3509,"interventions":3510},[89],[3059,3060,3061,3062,3063,3064,3065,3066],[3068,3069,3070,3043],{"trials":3512,"activeCount":100},[],{"trials":3514,"activeCount":100},[],{"trials":3516,"activeCount":100},[],{"intervention":3069,"totalTrials":96,"cells":3518},{"EARLY_PHASE1":3519,"PHASE1":3521,"PHASE2":3523,"PHASE3":3529,"PHASE4":3531,"NA":3533},{"trials":3520,"activeCount":100},[],{"trials":3522,"activeCount":100},[],{"trials":3524,"activeCount":100},[3525],{"nctId":3052,"briefTitle":3053,"status":448,"phases":3526,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":677,"conditions":3527,"interventions":3528},[89],[3059,3060,3061,3062,3063,3064,3065,3066],[3068,3069,3070,3043],{"trials":3530,"activeCount":100},[],{"trials":3532,"activeCount":100},[],{"trials":3534,"activeCount":100},[],{"intervention":3070,"totalTrials":96,"cells":3536},{"EARLY_PHASE1":3537,"PHASE1":3539,"PHASE2":3541,"PHASE3":3547,"PHASE4":3549,"NA":3551},{"trials":3538,"activeCount":100},[],{"trials":3540,"activeCount":100},[],{"trials":3542,"activeCount":100},[3543],{"nctId":3052,"briefTitle":3053,"status":448,"phases":3544,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":677,"conditions":3545,"interventions":3546},[89],[3059,3060,3061,3062,3063,3064,3065,3066],[3068,3069,3070,3043],{"trials":3548,"activeCount":100},[],{"trials":3550,"activeCount":100},[],{"trials":3552,"activeCount":100},[],{"intervention":3554,"totalTrials":96,"cells":3555},"NBT-NM108",{"EARLY_PHASE1":3556,"PHASE1":3558,"PHASE2":3560,"PHASE3":3573,"PHASE4":3575,"NA":3577},{"trials":3557,"activeCount":100},[],{"trials":3559,"activeCount":100},[],{"trials":3561,"activeCount":100},[3562],{"nctId":3563,"briefTitle":3564,"status":448,"phases":3565,"primaryCompletion":3566,"completion":3567,"start":3568,"enrollment":3569,"conditions":3570,"interventions":3572},"NCT05541003","Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome",[89],"2023-05-29","2023-05-30","2023-01-06",12,[3571,34],"Prader-Willi Syndrome",[3554],{"trials":3574,"activeCount":100},[],{"trials":3576,"activeCount":100},[],{"trials":3578,"activeCount":100},[],{"intervention":619,"totalTrials":96,"cells":3580},{"EARLY_PHASE1":3581,"PHASE1":3583,"PHASE2":3585,"PHASE3":3591,"PHASE4":3593,"NA":3595},{"trials":3582,"activeCount":100},[],{"trials":3584,"activeCount":100},[],{"trials":3586,"activeCount":100},[3587],{"nctId":608,"briefTitle":609,"status":463,"phases":3588,"primaryCompletion":611,"completion":297,"start":612,"enrollment":22,"conditions":3589,"interventions":3590},[89],[571,614,585,587,588,593,615,616,617],[619,56],{"trials":3592,"activeCount":100},[],{"trials":3594,"activeCount":100},[],{"trials":3596,"activeCount":100},[],{"intervention":3598,"totalTrials":96,"cells":3599},"Green Tea",{"EARLY_PHASE1":3600,"PHASE1":3602,"PHASE2":3604,"PHASE3":3615,"PHASE4":3617,"NA":3619},{"trials":3601,"activeCount":100},[],{"trials":3603,"activeCount":100},[],{"trials":3605,"activeCount":100},[3606],{"nctId":3607,"briefTitle":3608,"status":463,"phases":3609,"primaryCompletion":3610,"completion":3610,"start":3611,"enrollment":3612,"conditions":3613,"interventions":3614},"NCT00134381","Green Tea and Ultraviolet Light-induced Skin Damage",[89],"2012-11","2003-05",68,[1759],[3598],{"trials":3616,"activeCount":100},[],{"trials":3618,"activeCount":100},[],{"trials":3620,"activeCount":100},[],{"intervention":2914,"totalTrials":96,"cells":3622},{"EARLY_PHASE1":3623,"PHASE1":3625,"PHASE2":3627,"PHASE3":3633,"PHASE4":3635,"NA":3637},{"trials":3624,"activeCount":100},[],{"trials":3626,"activeCount":100},[],{"trials":3628,"activeCount":100},[3629],{"nctId":2889,"briefTitle":2890,"status":448,"phases":3630,"primaryCompletion":2892,"completion":2892,"start":2893,"enrollment":2894,"conditions":3631,"interventions":3632},[89],[2896,2897,2898,2899,2900,2901,2902,2903,2904,2905,2906,2907,2908,2909,2910,2911,2912],[2870,2914,2845],{"trials":3634,"activeCount":100},[],{"trials":3636,"activeCount":100},[],{"trials":3638,"activeCount":100},[],{"intervention":3640,"totalTrials":96,"cells":3641},"2-deoxyglucose",{"EARLY_PHASE1":3642,"PHASE1":3644,"PHASE2":3646,"PHASE3":3655,"PHASE4":3657,"NA":3659},{"trials":3643,"activeCount":100},[],{"trials":3645,"activeCount":100},[],{"trials":3647,"activeCount":100},[3648],{"nctId":3649,"briefTitle":3650,"status":463,"phases":3651,"primaryCompletion":2920,"completion":2920,"start":3652,"enrollment":3569,"conditions":3653,"interventions":3654},"NCT00633087","A Phase I\u002FII Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer",[88,89],"2006-11",[18],[3640],{"trials":3656,"activeCount":100},[],{"trials":3658,"activeCount":100},[],{"trials":3660,"activeCount":100},[],{"intervention":3662,"totalTrials":96,"cells":3663},"paroxetine",{"EARLY_PHASE1":3664,"PHASE1":3666,"PHASE2":3668,"PHASE3":3679,"PHASE4":3681,"NA":3683},{"trials":3665,"activeCount":100},[],{"trials":3667,"activeCount":100},[],{"trials":3669,"activeCount":100},[3670],{"nctId":3671,"briefTitle":3672,"status":448,"phases":3673,"primaryCompletion":2893,"completion":2893,"start":3674,"enrollment":3675,"conditions":3676,"interventions":3677},"NCT00062738","Treatment of Depression in Parkinson's Disease Trial",[89],"2003-06",52,[30,24],[3662,3678],"Nortriptyline",{"trials":3680,"activeCount":100},[],{"trials":3682,"activeCount":100},[],{"trials":3684,"activeCount":100},[],{"intervention":3678,"totalTrials":96,"cells":3686},{"EARLY_PHASE1":3687,"PHASE1":3689,"PHASE2":3691,"PHASE3":3697,"PHASE4":3699,"NA":3701},{"trials":3688,"activeCount":100},[],{"trials":3690,"activeCount":100},[],{"trials":3692,"activeCount":100},[3693],{"nctId":3671,"briefTitle":3672,"status":448,"phases":3694,"primaryCompletion":2893,"completion":2893,"start":3674,"enrollment":3675,"conditions":3695,"interventions":3696},[89],[30,24],[3662,3678],{"trials":3698,"activeCount":100},[],{"trials":3700,"activeCount":100},[],{"trials":3702,"activeCount":100},[],{"intervention":2843,"totalTrials":96,"cells":3704},{"EARLY_PHASE1":3705,"PHASE1":3707,"PHASE2":3709,"PHASE3":3715,"PHASE4":3717,"NA":3719},{"trials":3706,"activeCount":100},[],{"trials":3708,"activeCount":100},[],{"trials":3710,"activeCount":100},[3711],{"nctId":2835,"briefTitle":2836,"status":448,"phases":3712,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":1431,"conditions":3713,"interventions":3714},[89],[2841],[2843,2844,2815,2845,2846,2847,2848,2849,2850,2851,2852,2853],{"trials":3716,"activeCount":100},[],{"trials":3718,"activeCount":100},[],{"trials":3720,"activeCount":100},[],{"intervention":2844,"totalTrials":96,"cells":3722},{"EARLY_PHASE1":3723,"PHASE1":3725,"PHASE2":3727,"PHASE3":3733,"PHASE4":3735,"NA":3737},{"trials":3724,"activeCount":100},[],{"trials":3726,"activeCount":100},[],{"trials":3728,"activeCount":100},[3729],{"nctId":2835,"briefTitle":2836,"status":448,"phases":3730,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":1431,"conditions":3731,"interventions":3732},[89],[2841],[2843,2844,2815,2845,2846,2847,2848,2849,2850,2851,2852,2853],{"trials":3734,"activeCount":100},[],{"trials":3736,"activeCount":100},[],{"trials":3738,"activeCount":100},[],{"intervention":2846,"totalTrials":96,"cells":3740},{"EARLY_PHASE1":3741,"PHASE1":3743,"PHASE2":3745,"PHASE3":3751,"PHASE4":3753,"NA":3755},{"trials":3742,"activeCount":100},[],{"trials":3744,"activeCount":100},[],{"trials":3746,"activeCount":100},[3747],{"nctId":2835,"briefTitle":2836,"status":448,"phases":3748,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":1431,"conditions":3749,"interventions":3750},[89],[2841],[2843,2844,2815,2845,2846,2847,2848,2849,2850,2851,2852,2853],{"trials":3752,"activeCount":100},[],{"trials":3754,"activeCount":100},[],{"trials":3756,"activeCount":100},[],{"intervention":2848,"totalTrials":96,"cells":3758},{"EARLY_PHASE1":3759,"PHASE1":3761,"PHASE2":3763,"PHASE3":3769,"PHASE4":3771,"NA":3773},{"trials":3760,"activeCount":100},[],{"trials":3762,"activeCount":100},[],{"trials":3764,"activeCount":100},[3765],{"nctId":2835,"briefTitle":2836,"status":448,"phases":3766,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":1431,"conditions":3767,"interventions":3768},[89],[2841],[2843,2844,2815,2845,2846,2847,2848,2849,2850,2851,2852,2853],{"trials":3770,"activeCount":100},[],{"trials":3772,"activeCount":100},[],{"trials":3774,"activeCount":100},[],{"intervention":2849,"totalTrials":96,"cells":3776},{"EARLY_PHASE1":3777,"PHASE1":3779,"PHASE2":3781,"PHASE3":3787,"PHASE4":3789,"NA":3791},{"trials":3778,"activeCount":100},[],{"trials":3780,"activeCount":100},[],{"trials":3782,"activeCount":100},[3783],{"nctId":2835,"briefTitle":2836,"status":448,"phases":3784,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":1431,"conditions":3785,"interventions":3786},[89],[2841],[2843,2844,2815,2845,2846,2847,2848,2849,2850,2851,2852,2853],{"trials":3788,"activeCount":100},[],{"trials":3790,"activeCount":100},[],{"trials":3792,"activeCount":100},[],{"intervention":2850,"totalTrials":96,"cells":3794},{"EARLY_PHASE1":3795,"PHASE1":3797,"PHASE2":3799,"PHASE3":3805,"PHASE4":3807,"NA":3809},{"trials":3796,"activeCount":100},[],{"trials":3798,"activeCount":100},[],{"trials":3800,"activeCount":100},[3801],{"nctId":2835,"briefTitle":2836,"status":448,"phases":3802,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":1431,"conditions":3803,"interventions":3804},[89],[2841],[2843,2844,2815,2845,2846,2847,2848,2849,2850,2851,2852,2853],{"trials":3806,"activeCount":100},[],{"trials":3808,"activeCount":100},[],{"trials":3810,"activeCount":100},[],{"intervention":2851,"totalTrials":96,"cells":3812},{"EARLY_PHASE1":3813,"PHASE1":3815,"PHASE2":3817,"PHASE3":3823,"PHASE4":3825,"NA":3827},{"trials":3814,"activeCount":100},[],{"trials":3816,"activeCount":100},[],{"trials":3818,"activeCount":100},[3819],{"nctId":2835,"briefTitle":2836,"status":448,"phases":3820,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":1431,"conditions":3821,"interventions":3822},[89],[2841],[2843,2844,2815,2845,2846,2847,2848,2849,2850,2851,2852,2853],{"trials":3824,"activeCount":100},[],{"trials":3826,"activeCount":100},[],{"trials":3828,"activeCount":100},[],{"intervention":2852,"totalTrials":96,"cells":3830},{"EARLY_PHASE1":3831,"PHASE1":3833,"PHASE2":3835,"PHASE3":3841,"PHASE4":3843,"NA":3845},{"trials":3832,"activeCount":100},[],{"trials":3834,"activeCount":100},[],{"trials":3836,"activeCount":100},[3837],{"nctId":2835,"briefTitle":2836,"status":448,"phases":3838,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":1431,"conditions":3839,"interventions":3840},[89],[2841],[2843,2844,2815,2845,2846,2847,2848,2849,2850,2851,2852,2853],{"trials":3842,"activeCount":100},[],{"trials":3844,"activeCount":100},[],{"trials":3846,"activeCount":100},[],{"intervention":2853,"totalTrials":96,"cells":3848},{"EARLY_PHASE1":3849,"PHASE1":3851,"PHASE2":3853,"PHASE3":3859,"PHASE4":3861,"NA":3863},{"trials":3850,"activeCount":100},[],{"trials":3852,"activeCount":100},[],{"trials":3854,"activeCount":100},[3855],{"nctId":2835,"briefTitle":2836,"status":448,"phases":3856,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":1431,"conditions":3857,"interventions":3858},[89],[2841],[2843,2844,2815,2845,2846,2847,2848,2849,2850,2851,2852,2853],{"trials":3860,"activeCount":100},[],{"trials":3862,"activeCount":100},[],{"trials":3864,"activeCount":100},[],{"intervention":3866,"totalTrials":96,"cells":3867},"68Gallium Citrate",{"EARLY_PHASE1":3868,"PHASE1":3870,"PHASE2":3872,"PHASE3":3885,"PHASE4":3887,"NA":3889},{"trials":3869,"activeCount":100},[],{"trials":3871,"activeCount":100},[],{"trials":3873,"activeCount":100},[3874],{"nctId":3875,"briefTitle":3876,"status":1968,"phases":3877,"primaryCompletion":3878,"completion":3879,"start":3880,"enrollment":3881,"conditions":3882,"interventions":3884},"NCT03116945","Novel Gallium Imaging in Hepatocellular Carcinoma",[89],"2020-06","2020-12","2016-06",18,[3883],"Hepatocellular Carcinoma",[3866],{"trials":3886,"activeCount":100},[],{"trials":3888,"activeCount":100},[],{"trials":3890,"activeCount":100},[],{"intervention":3892,"totalTrials":96,"cells":3893},"Propranolol",{"EARLY_PHASE1":3894,"PHASE1":3896,"PHASE2":3898,"PHASE3":3912,"PHASE4":3914,"NA":3916},{"trials":3895,"activeCount":100},[],{"trials":3897,"activeCount":100},[],{"trials":3899,"activeCount":100},[3900],{"nctId":3901,"briefTitle":3902,"status":448,"phases":3903,"primaryCompletion":3904,"completion":3904,"start":3905,"enrollment":28,"conditions":3906,"interventions":3911},"NCT04047355","Propranolol for Challenging Behaviors in Autism",[89],"2023-09-30","2021-02-11",[21,3907,3908,3909,3910],"Developmental Disability","Aggression","Self-Injurious Behavior","Challenging Behavior",[3892],{"trials":3913,"activeCount":100},[],{"trials":3915,"activeCount":100},[],{"trials":3917,"activeCount":100},[],{"intervention":3919,"totalTrials":96,"cells":3920},"Hydroxychloroquine Sulfate + Azithromycin",{"EARLY_PHASE1":3921,"PHASE1":3923,"PHASE2":3925,"PHASE3":3938,"PHASE4":3940,"NA":3942},{"trials":3922,"activeCount":100},[],{"trials":3924,"activeCount":100},[],{"trials":3926,"activeCount":100},[3927],{"nctId":3928,"briefTitle":3929,"status":463,"phases":3930,"primaryCompletion":3317,"completion":3317,"start":3931,"enrollment":3932,"conditions":3933,"interventions":3936},"NCT04336332","Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19",[89],"2020-04-01",75,[3934,3935],"SARS-CoV-2","COVID-19",[3919,3937],"Hydroxychloroquine Sulfate",{"trials":3939,"activeCount":100},[],{"trials":3941,"activeCount":100},[],{"trials":3943,"activeCount":100},[],{"intervention":3937,"totalTrials":96,"cells":3945},{"EARLY_PHASE1":3946,"PHASE1":3948,"PHASE2":3950,"PHASE3":3956,"PHASE4":3958,"NA":3960},{"trials":3947,"activeCount":100},[],{"trials":3949,"activeCount":100},[],{"trials":3951,"activeCount":100},[3952],{"nctId":3928,"briefTitle":3929,"status":463,"phases":3953,"primaryCompletion":3317,"completion":3317,"start":3931,"enrollment":3932,"conditions":3954,"interventions":3955},[89],[3934,3935],[3919,3937],{"trials":3957,"activeCount":100},[],{"trials":3959,"activeCount":100},[],{"trials":3961,"activeCount":100},[],{"intervention":3963,"totalTrials":96,"cells":3964},"sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C",{"EARLY_PHASE1":3965,"PHASE1":3967,"PHASE2":3969,"PHASE3":3977,"PHASE4":3979,"NA":3981},{"trials":3966,"activeCount":100},[],{"trials":3968,"activeCount":100},[],{"trials":3970,"activeCount":100},[3971],{"nctId":3972,"briefTitle":3973,"status":448,"phases":3974,"primaryCompletion":2734,"completion":2734,"start":1902,"enrollment":9,"conditions":3975,"interventions":3976},"NCT00949182","Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery",[89],[2830],[3963],{"trials":3978,"activeCount":100},[],{"trials":3980,"activeCount":100},[],{"trials":3982,"activeCount":100},[],{"intervention":3984,"totalTrials":96,"cells":3985},"Sorafenib",{"EARLY_PHASE1":3986,"PHASE1":3988,"PHASE2":3990,"PHASE3":4002,"PHASE4":4004,"NA":4006},{"trials":3987,"activeCount":100},[],{"trials":3989,"activeCount":100},[],{"trials":3991,"activeCount":100},[3992],{"nctId":3993,"briefTitle":3994,"status":448,"phases":3995,"primaryCompletion":3996,"completion":3997,"start":3998,"enrollment":3675,"conditions":3999,"interventions":4000},"NCT00634634","Phase I\u002FII Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer",[88,89],"2019-04-20","2023-04-28","2008-08-11",[543],[3984,4001],"Letrozole",{"trials":4003,"activeCount":100},[],{"trials":4005,"activeCount":100},[],{"trials":4007,"activeCount":100},[],{"intervention":4001,"totalTrials":96,"cells":4009},{"EARLY_PHASE1":4010,"PHASE1":4012,"PHASE2":4014,"PHASE3":4020,"PHASE4":4022,"NA":4024},{"trials":4011,"activeCount":100},[],{"trials":4013,"activeCount":100},[],{"trials":4015,"activeCount":100},[4016],{"nctId":3993,"briefTitle":3994,"status":448,"phases":4017,"primaryCompletion":3996,"completion":3997,"start":3998,"enrollment":3675,"conditions":4018,"interventions":4019},[88,89],[543],[3984,4001],{"trials":4021,"activeCount":100},[],{"trials":4023,"activeCount":100},[],{"trials":4025,"activeCount":100},[],{"intervention":4027,"totalTrials":96,"cells":4028},"Transdermal Nicotine patch",{"EARLY_PHASE1":4029,"PHASE1":4031,"PHASE2":4033,"PHASE3":4043,"PHASE4":4045,"NA":4047},{"trials":4030,"activeCount":100},[],{"trials":4032,"activeCount":100},[],{"trials":4034,"activeCount":100},[4035],{"nctId":4036,"briefTitle":4037,"status":448,"phases":4038,"primaryCompletion":4039,"completion":4039,"start":4040,"enrollment":22,"conditions":4041,"interventions":4042},"NCT03972137","Heart Rate Variability Biofeedback for Smoking Cessation",[89],"2020-02-20","2019-04-24",[2337],[4027],{"trials":4044,"activeCount":100},[],{"trials":4046,"activeCount":100},[],{"trials":4048,"activeCount":100},[],{"intervention":3085,"totalTrials":96,"cells":4050},{"EARLY_PHASE1":4051,"PHASE1":4053,"PHASE2":4055,"PHASE3":4061,"PHASE4":4063,"NA":4065},{"trials":4052,"activeCount":100},[],{"trials":4054,"activeCount":100},[],{"trials":4056,"activeCount":100},[4057],{"nctId":3072,"briefTitle":3073,"status":1899,"phases":4058,"primaryCompletion":2114,"completion":2114,"start":3075,"enrollment":100,"conditions":4059,"interventions":4060},[89],[3077,3078,3079,3080,3081,3082,3083],[3085,3086,3043],{"trials":4062,"activeCount":100},[],{"trials":4064,"activeCount":100},[],{"trials":4066,"activeCount":100},[],{"intervention":3086,"totalTrials":96,"cells":4068},{"EARLY_PHASE1":4069,"PHASE1":4071,"PHASE2":4073,"PHASE3":4079,"PHASE4":4081,"NA":4083},{"trials":4070,"activeCount":100},[],{"trials":4072,"activeCount":100},[],{"trials":4074,"activeCount":100},[4075],{"nctId":3072,"briefTitle":3073,"status":1899,"phases":4076,"primaryCompletion":2114,"completion":2114,"start":3075,"enrollment":100,"conditions":4077,"interventions":4078},[89],[3077,3078,3079,3080,3081,3082,3083],[3085,3086,3043],{"trials":4080,"activeCount":100},[],{"trials":4082,"activeCount":100},[],{"trials":4084,"activeCount":100},[],{"intervention":2982,"totalTrials":96,"cells":4086},{"EARLY_PHASE1":4087,"PHASE1":4089,"PHASE2":4091,"PHASE3":4097,"PHASE4":4099,"NA":4101},{"trials":4088,"activeCount":100},[],{"trials":4090,"activeCount":100},[],{"trials":4092,"activeCount":100},[4093],{"nctId":2975,"briefTitle":2976,"status":463,"phases":4094,"primaryCompletion":2978,"completion":2978,"start":2979,"enrollment":22,"conditions":4095,"interventions":4096},[89],[2972],[2958,2982],{"trials":4098,"activeCount":100},[],{"trials":4100,"activeCount":100},[],{"trials":4102,"activeCount":100},[],{"intervention":2861,"totalTrials":96,"cells":4104},{"EARLY_PHASE1":4105,"PHASE1":4107,"PHASE2":4109,"PHASE3":4115,"PHASE4":4117,"NA":4119},{"trials":4106,"activeCount":100},[],{"trials":4108,"activeCount":100},[],{"trials":4110,"activeCount":100},[4111],{"nctId":2855,"briefTitle":2856,"status":448,"phases":4112,"primaryCompletion":2803,"completion":2803,"start":2858,"enrollment":16,"conditions":4113,"interventions":4114},[89],[18],[2861,2862],{"trials":4116,"activeCount":100},[],{"trials":4118,"activeCount":100},[],{"trials":4120,"activeCount":100},[],{"intervention":871,"totalTrials":96,"cells":4122},{"EARLY_PHASE1":4123,"PHASE1":4125,"PHASE2":4127,"PHASE3":4133,"PHASE4":4135,"NA":4137},{"trials":4124,"activeCount":100},[],{"trials":4126,"activeCount":100},[],{"trials":4128,"activeCount":100},[4129],{"nctId":860,"briefTitle":861,"status":463,"phases":4130,"primaryCompletion":863,"completion":864,"start":865,"enrollment":866,"conditions":4131,"interventions":4132},[89],[15,543,868,869],[669,871],{"trials":4134,"activeCount":100},[],{"trials":4136,"activeCount":100},[],{"trials":4138,"activeCount":100},[],{"intervention":545,"totalTrials":96,"cells":4140},{"EARLY_PHASE1":4141,"PHASE1":4143,"PHASE2":4145,"PHASE3":4151,"PHASE4":4153,"NA":4155},{"trials":4142,"activeCount":100},[],{"trials":4144,"activeCount":100},[],{"trials":4146,"activeCount":100},[4147],{"nctId":535,"briefTitle":536,"status":448,"phases":4148,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":4149,"interventions":4150},[89],[543],[545,439,488],{"trials":4152,"activeCount":100},[],{"trials":4154,"activeCount":100},[],{"trials":4156,"activeCount":100},[],{"intervention":2923,"totalTrials":96,"cells":4158},{"EARLY_PHASE1":4159,"PHASE1":4161,"PHASE2":4163,"PHASE3":4169,"PHASE4":4171,"NA":4173},{"trials":4160,"activeCount":100},[],{"trials":4162,"activeCount":100},[],{"trials":4164,"activeCount":100},[4165],{"nctId":2916,"briefTitle":2917,"status":463,"phases":4166,"primaryCompletion":2919,"completion":2139,"start":2920,"enrollment":96,"conditions":4167,"interventions":4168},[89],[2883],[2923,2885,2924],{"trials":4170,"activeCount":100},[],{"trials":4172,"activeCount":100},[],{"trials":4174,"activeCount":100},[],{"intervention":4176,"totalTrials":546,"cells":4177},"Endotoxin, Lipopolysaccharide, LPS",{"EARLY_PHASE1":4178,"PHASE1":4180,"PHASE2":4212,"PHASE3":4214,"PHASE4":4216,"NA":4218},{"trials":4179,"activeCount":100},[],{"trials":4181,"activeCount":100},[4182,4192,4201],{"nctId":4183,"briefTitle":4184,"status":448,"phases":4185,"primaryCompletion":4186,"completion":4186,"start":4187,"enrollment":4188,"conditions":4189,"interventions":4191},"NCT00820989","Inflammation and the Host Response to Injury (In Healthy Volunteers)",[88],"2011-02","2000-02",116,[4190],"Immune System",[4176],{"nctId":4193,"briefTitle":4194,"status":448,"phases":4195,"primaryCompletion":4196,"completion":4196,"start":4196,"enrollment":4197,"conditions":4198,"interventions":4199},"NCT00753402","The Effects of Epinephrine in Endotoxemia in Normal Volunteers",[88],"2012-02",37,[4190],[4176,4200],"Endotoxin, Epinephrine",{"nctId":4202,"briefTitle":4203,"status":448,"phases":4204,"primaryCompletion":4205,"completion":4205,"start":4206,"enrollment":3569,"conditions":4207,"interventions":4209},"NCT01064986","The Effects of Hydrocortisone in Endotoxemia in Normal Volunteers",[88],"2012-12","2010-02",[4208],"Infections",[4176,4210,4211],"Endotoxin, Lipopolysaccharide, LPS \u002FEpinephrine","Hydrocortisone",{"trials":4213,"activeCount":100},[],{"trials":4215,"activeCount":100},[],{"trials":4217,"activeCount":100},[],{"trials":4219,"activeCount":100},[],{"intervention":4221,"totalTrials":705,"cells":4222},"Oral ONC201",{"EARLY_PHASE1":4223,"PHASE1":4225,"PHASE2":4246,"PHASE3":4248,"PHASE4":4250,"NA":4252},{"trials":4224,"activeCount":100},[],{"trials":4226,"activeCount":100},[4227,4236],{"nctId":4228,"briefTitle":4229,"status":448,"phases":4230,"primaryCompletion":611,"completion":4231,"start":4232,"enrollment":2335,"conditions":4233,"interventions":4235},"NCT02250781","Oral ONC201 in Treating Patients With Advanced Solid Tumors",[88],"2018-10-25","2015-01-12",[4234],"Solid Tumors",[4221],{"nctId":4237,"briefTitle":4238,"status":448,"phases":4239,"primaryCompletion":611,"completion":4240,"start":4241,"enrollment":4242,"conditions":4243,"interventions":4245},"NCT02324621","Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors",[88],"2018-10-23","2015-02-20",26,[4244],"Unspecified Adult Solid Tumor",[4221],{"trials":4247,"activeCount":100},[],{"trials":4249,"activeCount":100},[],{"trials":4251,"activeCount":100},[],{"trials":4253,"activeCount":100},[],{"intervention":4255,"totalTrials":96,"cells":4256},"High Fiber supplement",{"EARLY_PHASE1":4257,"PHASE1":4259,"PHASE2":4270,"PHASE3":4272,"PHASE4":4274,"NA":4276},{"trials":4258,"activeCount":100},[],{"trials":4260,"activeCount":100},[4261],{"nctId":4262,"briefTitle":4263,"status":1968,"phases":4264,"primaryCompletion":4265,"completion":4266,"start":4267,"enrollment":1431,"conditions":4268,"interventions":4269},"NCT04976959","High Fiber in Parkinson's Disease",[88],"2025-06-30","2025-08-31","2021-07-08",[30],[4255],{"trials":4271,"activeCount":100},[],{"trials":4273,"activeCount":100},[],{"trials":4275,"activeCount":100},[],{"trials":4277,"activeCount":100},[],{"intervention":4279,"totalTrials":96,"cells":4280},"Besivance Treatment Group",{"EARLY_PHASE1":4281,"PHASE1":4283,"PHASE2":4296,"PHASE3":4298,"PHASE4":4300,"NA":4302},{"trials":4282,"activeCount":100},[],{"trials":4284,"activeCount":100},[4285],{"nctId":4286,"briefTitle":4287,"status":448,"phases":4288,"primaryCompletion":4289,"completion":4289,"start":4290,"enrollment":4291,"conditions":4292,"interventions":4294},"NCT01431170","Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children",[88],"2014-06","2011-09",24,[4293],"Congenital Nasolacrimal Duct Obstruction",[4279,4295],"Polytrim Treatment Group",{"trials":4297,"activeCount":100},[],{"trials":4299,"activeCount":100},[],{"trials":4301,"activeCount":100},[],{"trials":4303,"activeCount":100},[],{"intervention":4295,"totalTrials":96,"cells":4305},{"EARLY_PHASE1":4306,"PHASE1":4308,"PHASE2":4314,"PHASE3":4316,"PHASE4":4318,"NA":4320},{"trials":4307,"activeCount":100},[],{"trials":4309,"activeCount":100},[4310],{"nctId":4286,"briefTitle":4287,"status":448,"phases":4311,"primaryCompletion":4289,"completion":4289,"start":4290,"enrollment":4291,"conditions":4312,"interventions":4313},[88],[4293],[4279,4295],{"trials":4315,"activeCount":100},[],{"trials":4317,"activeCount":100},[],{"trials":4319,"activeCount":100},[],{"trials":4321,"activeCount":100},[],{"intervention":599,"totalTrials":96,"cells":4323},{"EARLY_PHASE1":4324,"PHASE1":4326,"PHASE2":4332,"PHASE3":4334,"PHASE4":4336,"NA":4338},{"trials":4325,"activeCount":100},[],{"trials":4327,"activeCount":100},[4328],{"nctId":561,"briefTitle":562,"status":448,"phases":4329,"primaryCompletion":564,"completion":565,"start":566,"enrollment":567,"conditions":4330,"interventions":4331},[88],[569,570,571,572,573,574,575,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592,593,594,595,596,597],[599,600,56],{"trials":4333,"activeCount":100},[],{"trials":4335,"activeCount":100},[],{"trials":4337,"activeCount":100},[],{"trials":4339,"activeCount":100},[],{"intervention":600,"totalTrials":96,"cells":4341},{"EARLY_PHASE1":4342,"PHASE1":4344,"PHASE2":4350,"PHASE3":4352,"PHASE4":4354,"NA":4356},{"trials":4343,"activeCount":100},[],{"trials":4345,"activeCount":100},[4346],{"nctId":561,"briefTitle":562,"status":448,"phases":4347,"primaryCompletion":564,"completion":565,"start":566,"enrollment":567,"conditions":4348,"interventions":4349},[88],[569,570,571,572,573,574,575,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592,593,594,595,596,597],[599,600,56],{"trials":4351,"activeCount":100},[],{"trials":4353,"activeCount":100},[],{"trials":4355,"activeCount":100},[],{"trials":4357,"activeCount":100},[],{"intervention":4200,"totalTrials":96,"cells":4359},{"EARLY_PHASE1":4360,"PHASE1":4362,"PHASE2":4368,"PHASE3":4370,"PHASE4":4372,"NA":4374},{"trials":4361,"activeCount":100},[],{"trials":4363,"activeCount":100},[4364],{"nctId":4193,"briefTitle":4194,"status":448,"phases":4365,"primaryCompletion":4196,"completion":4196,"start":4196,"enrollment":4197,"conditions":4366,"interventions":4367},[88],[4190],[4176,4200],{"trials":4369,"activeCount":100},[],{"trials":4371,"activeCount":100},[],{"trials":4373,"activeCount":100},[],{"trials":4375,"activeCount":100},[],{"intervention":4377,"totalTrials":96,"cells":4378},"BKM120",{"EARLY_PHASE1":4379,"PHASE1":4381,"PHASE2":4393,"PHASE3":4395,"PHASE4":4397,"NA":4399},{"trials":4380,"activeCount":100},[],{"trials":4382,"activeCount":100},[4383],{"nctId":4384,"briefTitle":4385,"status":1899,"phases":4386,"primaryCompletion":505,"completion":505,"start":4387,"enrollment":100,"conditions":4388,"interventions":4391},"NCT02117817","Phase I BKM120\u002FAbraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer",[88],"2015-02",[2831,730,4389,4390],"Recurrent Ovarian Cancer","Recurrent Endometrial Cancer",[4377,4392],"Nabpaclitaxel",{"trials":4394,"activeCount":100},[],{"trials":4396,"activeCount":100},[],{"trials":4398,"activeCount":100},[],{"trials":4400,"activeCount":100},[],{"intervention":4392,"totalTrials":96,"cells":4402},{"EARLY_PHASE1":4403,"PHASE1":4405,"PHASE2":4411,"PHASE3":4413,"PHASE4":4415,"NA":4417},{"trials":4404,"activeCount":100},[],{"trials":4406,"activeCount":100},[4407],{"nctId":4384,"briefTitle":4385,"status":1899,"phases":4408,"primaryCompletion":505,"completion":505,"start":4387,"enrollment":100,"conditions":4409,"interventions":4410},[88],[2831,730,4389,4390],[4377,4392],{"trials":4412,"activeCount":100},[],{"trials":4414,"activeCount":100},[],{"trials":4416,"activeCount":100},[],{"trials":4418,"activeCount":100},[],{"intervention":4420,"totalTrials":96,"cells":4421},"Atezolizumab 1200 MG in 20 ML",{"EARLY_PHASE1":4422,"PHASE1":4424,"PHASE2":4438,"PHASE3":4440,"PHASE4":4442,"NA":4444},{"trials":4423,"activeCount":100},[],{"trials":4425,"activeCount":100},[4426],{"nctId":4427,"briefTitle":4428,"status":463,"phases":4429,"primaryCompletion":4430,"completion":4431,"start":4432,"enrollment":1732,"conditions":4433,"interventions":4436},"NCT04081688","Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC",[88],"2022-04-27","2024-04-30","2019-09-11",[4434,4435],"Refractory Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8",[4420,4437],"Varlilumab 3 mg\u002Fkg",{"trials":4439,"activeCount":100},[],{"trials":4441,"activeCount":100},[],{"trials":4443,"activeCount":100},[],{"trials":4445,"activeCount":100},[],{"intervention":4437,"totalTrials":96,"cells":4447},{"EARLY_PHASE1":4448,"PHASE1":4450,"PHASE2":4456,"PHASE3":4458,"PHASE4":4460,"NA":4462},{"trials":4449,"activeCount":100},[],{"trials":4451,"activeCount":100},[4452],{"nctId":4427,"briefTitle":4428,"status":463,"phases":4453,"primaryCompletion":4430,"completion":4431,"start":4432,"enrollment":1732,"conditions":4454,"interventions":4455},[88],[4434,4435],[4420,4437],{"trials":4457,"activeCount":100},[],{"trials":4459,"activeCount":100},[],{"trials":4461,"activeCount":100},[],{"trials":4463,"activeCount":100},[],{"intervention":4465,"totalTrials":96,"cells":4466},"AN0025",{"EARLY_PHASE1":4467,"PHASE1":4469,"PHASE2":4480,"PHASE3":4482,"PHASE4":4484,"NA":4486},{"trials":4468,"activeCount":100},[],{"trials":4470,"activeCount":100},[4471],{"nctId":4472,"briefTitle":4473,"status":1899,"phases":4474,"primaryCompletion":984,"completion":4475,"start":4476,"enrollment":100,"conditions":4477,"interventions":4479},"NCT05358691","A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants",[88],"2028-06-01","2024-11-01",[4478],"Lung Cancer Stage III",[4465],{"trials":4481,"activeCount":100},[],{"trials":4483,"activeCount":100},[],{"trials":4485,"activeCount":100},[],{"trials":4487,"activeCount":100},[],{"intervention":4210,"totalTrials":96,"cells":4489},{"EARLY_PHASE1":4490,"PHASE1":4492,"PHASE2":4498,"PHASE3":4500,"PHASE4":4502,"NA":4504},{"trials":4491,"activeCount":100},[],{"trials":4493,"activeCount":100},[4494],{"nctId":4202,"briefTitle":4203,"status":448,"phases":4495,"primaryCompletion":4205,"completion":4205,"start":4206,"enrollment":3569,"conditions":4496,"interventions":4497},[88],[4208],[4176,4210,4211],{"trials":4499,"activeCount":100},[],{"trials":4501,"activeCount":100},[],{"trials":4503,"activeCount":100},[],{"trials":4505,"activeCount":100},[],{"intervention":4507,"totalTrials":96,"cells":4508},"ADT",{"EARLY_PHASE1":4509,"PHASE1":4511,"PHASE2":4524,"PHASE3":4526,"PHASE4":4528,"NA":4530},{"trials":4510,"activeCount":100},[],{"trials":4512,"activeCount":100},[4513],{"nctId":4514,"briefTitle":4515,"status":448,"phases":4516,"primaryCompletion":4517,"completion":4517,"start":4518,"enrollment":4242,"conditions":4519,"interventions":4523},"NCT02458716","Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer",[88],"2020-01-14","2015-03-06",[4520,4521,4522],"Metastatic Prostate Carcinoma","Metastatic Prostatic Adenocarcinoma","Prostate Carcinoma Metastatic to the Bone",[4507],{"trials":4525,"activeCount":100},[],{"trials":4527,"activeCount":100},[],{"trials":4529,"activeCount":100},[],{"trials":4531,"activeCount":100},[],{"intervention":4533,"totalTrials":96,"cells":4534},"Tolcapone 100 MG",{"EARLY_PHASE1":4535,"PHASE1":4537,"PHASE2":4549,"PHASE3":4551,"PHASE4":4553,"NA":4555},{"trials":4536,"activeCount":100},[],{"trials":4538,"activeCount":100},[4539],{"nctId":4540,"briefTitle":4541,"status":448,"phases":4542,"primaryCompletion":4543,"completion":4543,"start":4544,"enrollment":2805,"conditions":4545,"interventions":4547},"NCT05065671","Microbiome Derived Metabolism and Pharmacokinetics",[88],"2025-09-23","2022-02-01",[4546],"Microbial Colonization",[4533,4548],"Duloxetine 20 MG",{"trials":4550,"activeCount":100},[],{"trials":4552,"activeCount":100},[],{"trials":4554,"activeCount":100},[],{"trials":4556,"activeCount":100},[],{"intervention":4548,"totalTrials":96,"cells":4558},{"EARLY_PHASE1":4559,"PHASE1":4561,"PHASE2":4567,"PHASE3":4569,"PHASE4":4571,"NA":4573},{"trials":4560,"activeCount":100},[],{"trials":4562,"activeCount":100},[4563],{"nctId":4540,"briefTitle":4541,"status":448,"phases":4564,"primaryCompletion":4543,"completion":4543,"start":4544,"enrollment":2805,"conditions":4565,"interventions":4566},[88],[4546],[4533,4548],{"trials":4568,"activeCount":100},[],{"trials":4570,"activeCount":100},[],{"trials":4572,"activeCount":100},[],{"trials":4574,"activeCount":100},[],{"intervention":4576,"totalTrials":96,"cells":4577},"Panitumumab",{"EARLY_PHASE1":4578,"PHASE1":4580,"PHASE2":4594,"PHASE3":4596,"PHASE4":4598,"NA":4600},{"trials":4579,"activeCount":100},[],{"trials":4581,"activeCount":100},[4582],{"nctId":4583,"briefTitle":4584,"status":463,"phases":4585,"primaryCompletion":4586,"completion":4586,"start":4587,"enrollment":677,"conditions":4588,"interventions":4592},"NCT04163952","Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin",[88],"2025-03-28","2020-01-31",[4589,4590,4591],"Locally Advanced Skin Squamous Cell Carcinoma","Metastatic Skin Squamous Cell Carcinoma","Recurrent Skin Squamous Cell Carcinoma",[4576,4593],"Talimogene Laherparepvec",{"trials":4595,"activeCount":100},[],{"trials":4597,"activeCount":100},[],{"trials":4599,"activeCount":100},[],{"trials":4601,"activeCount":100},[],{"intervention":4593,"totalTrials":96,"cells":4603},{"EARLY_PHASE1":4604,"PHASE1":4606,"PHASE2":4612,"PHASE3":4614,"PHASE4":4616,"NA":4618},{"trials":4605,"activeCount":100},[],{"trials":4607,"activeCount":100},[4608],{"nctId":4583,"briefTitle":4584,"status":463,"phases":4609,"primaryCompletion":4586,"completion":4586,"start":4587,"enrollment":677,"conditions":4610,"interventions":4611},[88],[4589,4590,4591],[4576,4593],{"trials":4613,"activeCount":100},[],{"trials":4615,"activeCount":100},[],{"trials":4617,"activeCount":100},[],{"trials":4619,"activeCount":100},[],{"intervention":4621,"totalTrials":96,"cells":4622},"Nicotine lozenge",{"EARLY_PHASE1":4623,"PHASE1":4625,"PHASE2":4634,"PHASE3":4636,"PHASE4":4638,"NA":4640},{"trials":4624,"activeCount":100},[],{"trials":4626,"activeCount":100},[4627],{"nctId":4628,"briefTitle":4629,"status":448,"phases":4630,"primaryCompletion":2139,"completion":2139,"start":2234,"enrollment":2335,"conditions":4631,"interventions":4633},"NCT01654107","Persistence-Targeted Smoking Cessation",[88],[4632],"Tobacco Use Disorder",[4621],{"trials":4635,"activeCount":100},[],{"trials":4637,"activeCount":100},[],{"trials":4639,"activeCount":100},[],{"trials":4641,"activeCount":100},[],{"intervention":472,"totalTrials":96,"cells":4643},{"EARLY_PHASE1":4644,"PHASE1":4646,"PHASE2":4652,"PHASE3":4654,"PHASE4":4656,"NA":4658},{"trials":4645,"activeCount":100},[],{"trials":4647,"activeCount":100},[4648],{"nctId":461,"briefTitle":462,"status":463,"phases":4649,"primaryCompletion":465,"completion":465,"start":466,"enrollment":467,"conditions":4650,"interventions":4651},[88],[469,470],[472,459,439],{"trials":4653,"activeCount":100},[],{"trials":4655,"activeCount":100},[],{"trials":4657,"activeCount":100},[],{"trials":4659,"activeCount":100},[],{"intervention":4661,"totalTrials":96,"cells":4662},"Azithromycin",{"EARLY_PHASE1":4663,"PHASE1":4675,"PHASE2":4677,"PHASE3":4679,"PHASE4":4681,"NA":4683},{"trials":4664,"activeCount":100},[4665],{"nctId":4666,"briefTitle":4667,"status":448,"phases":4668,"primaryCompletion":4669,"completion":4669,"start":4670,"enrollment":1380,"conditions":4671,"interventions":4674},"NCT05961189","Influence of Short-Term Antibiotic Therapy on Exercise",[87],"2026-04-01","2023-09-01",[4672,4673],"Gastrointestinal Microbiome","Exercise",[4661],{"trials":4676,"activeCount":100},[],{"trials":4678,"activeCount":100},[],{"trials":4680,"activeCount":100},[],{"trials":4682,"activeCount":100},[],{"trials":4684,"activeCount":100},[],{"intervention":4686,"totalTrials":96,"cells":4687},"Mouthwash Product",{"EARLY_PHASE1":4688,"PHASE1":4699,"PHASE2":4701,"PHASE3":4703,"PHASE4":4705,"NA":4707},{"trials":4689,"activeCount":100},[4690],{"nctId":4691,"briefTitle":4692,"status":448,"phases":4693,"primaryCompletion":4694,"completion":4695,"start":4696,"enrollment":467,"conditions":4697,"interventions":4698},"NCT04931004","Oral Rinse to Reduced Expelled Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) During COVID-19 Infection",[87],"2022-05-24","2022-12-31","2021-07-21",[2426],[4686],{"trials":4700,"activeCount":100},[],{"trials":4702,"activeCount":100},[],{"trials":4704,"activeCount":100},[],{"trials":4706,"activeCount":100},[],{"trials":4708,"activeCount":100},[],{"intervention":4710,"totalTrials":96,"cells":4711},"LDE-225",{"EARLY_PHASE1":4712,"PHASE1":4721,"PHASE2":4723,"PHASE3":4725,"PHASE4":4727,"NA":4729},{"trials":4713,"activeCount":100},[4714],{"nctId":4715,"briefTitle":4716,"status":1899,"phases":4717,"primaryCompletion":4289,"completion":2827,"start":3610,"enrollment":100,"conditions":4718,"interventions":4720},"NCT01694589","A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer",[87],[4719],"Resectable Pancreatic Cancer",[4710],{"trials":4722,"activeCount":100},[],{"trials":4724,"activeCount":100},[],{"trials":4726,"activeCount":100},[],{"trials":4728,"activeCount":100},[],{"trials":4730,"activeCount":100},[],{"intervention":4732,"totalTrials":96,"cells":4733},"Irradiated Allogeneic Cells",{"EARLY_PHASE1":4734,"PHASE1":4759,"PHASE2":4761,"PHASE3":4763,"PHASE4":4765,"NA":4767},{"trials":4735,"activeCount":100},[4736],{"nctId":4737,"briefTitle":4738,"status":463,"phases":4739,"primaryCompletion":4740,"completion":4741,"start":3057,"enrollment":705,"conditions":4742,"interventions":4758},"NCT03272633","Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies",[87],"2022-06-30","2022-09-22",[4743,4744,4745,4746,4747,4748,4749,3062,4750,1618,4751,3079,4752,4753,3082,4754,4755,4756,4757],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia in Remission","Hematopoietic Cell Transplantation Recipient","JAK2 Gene Mutation","Loss of Chromosome 17p","Mantle Cell Lymphoma","Minimal Residual Disease","Non-Hodgkin Lymphoma","RAS Family Gene Mutation","Recurrent Hematologic Malignancy","Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma","Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Therapy-Related Acute Myeloid Leukemia","Therapy-Related Myelodysplastic Syndrome","TP53 Gene Mutation",[4732],{"trials":4760,"activeCount":100},[],{"trials":4762,"activeCount":100},[],{"trials":4764,"activeCount":100},[],{"trials":4766,"activeCount":100},[],{"trials":4768,"activeCount":100},[],{"intervention":4770,"totalTrials":96,"cells":4771},"Enzalutamide",{"EARLY_PHASE1":4772,"PHASE1":4784,"PHASE2":4786,"PHASE3":4788,"PHASE4":4790,"NA":4792},{"trials":4773,"activeCount":100},[4774],{"nctId":4775,"briefTitle":4776,"status":463,"phases":4777,"primaryCompletion":4778,"completion":4778,"start":4779,"enrollment":546,"conditions":4780,"interventions":4783},"NCT02885649","Enzalutamide Before Surgery in Treating Patients With Kidney Cancer",[87],"2020-03-02","2017-12-05",[4781,4782],"Clear Cell Renal Cell Carcinoma","Stage I Renal Cell Cancer",[4770],{"trials":4785,"activeCount":100},[],{"trials":4787,"activeCount":100},[],{"trials":4789,"activeCount":100},[],{"trials":4791,"activeCount":100},[],{"trials":4793,"activeCount":100},[],{"intervention":2365,"totalTrials":2702,"cells":4795},{"EARLY_PHASE1":4796,"PHASE1":4798,"PHASE2":4800,"PHASE3":4802,"PHASE4":4804,"NA":4810},{"trials":4797,"activeCount":100},[],{"trials":4799,"activeCount":100},[],{"trials":4801,"activeCount":100},[],{"trials":4803,"activeCount":100},[],{"trials":4805,"activeCount":100},[4806],{"nctId":2355,"briefTitle":2356,"status":448,"phases":4807,"primaryCompletion":2358,"completion":2359,"start":2360,"enrollment":2361,"conditions":4808,"interventions":4809},[91],[2363],[2342,2365],{"trials":4811,"activeCount":100},[4812,4822,4831],{"nctId":4813,"briefTitle":4814,"status":448,"phases":4815,"primaryCompletion":4816,"completion":4816,"start":4817,"enrollment":1380,"conditions":4818,"interventions":4820},"NCT01219569","Effects of Sevoflurane and Propofol on Light Flashed Evoked Pupillometry",[],"2010-01","2007-08",[4819],"Blindness",[2365,4821],"Sevoflurane",{"nctId":4823,"briefTitle":4824,"status":463,"phases":4825,"primaryCompletion":4826,"completion":2395,"start":4816,"enrollment":28,"conditions":4827,"interventions":4829},"NCT01031550","Isoflurane Preconditioning for Liver Resections",[92],"2012-01",[4828],"Liver Disease",[4830,2365],"isoflurane",{"nctId":4832,"briefTitle":4833,"status":463,"phases":4834,"primaryCompletion":2139,"completion":2139,"start":2395,"enrollment":541,"conditions":4835,"interventions":4838},"NCT01618539","Correlation of Bispectral Index Score and Total Intravenous Anesthesia (TIVA)",[],[4836,4837],"Benign\u002FMalignant Neoplasm","Long Bone Fracture",[2365],{"intervention":2845,"totalTrials":546,"cells":4840},{"EARLY_PHASE1":4841,"PHASE1":4843,"PHASE2":4845,"PHASE3":4855,"PHASE4":4857,"NA":4859},{"trials":4842,"activeCount":100},[],{"trials":4844,"activeCount":100},[],{"trials":4846,"activeCount":100},[4847,4851],{"nctId":2889,"briefTitle":2890,"status":448,"phases":4848,"primaryCompletion":2892,"completion":2892,"start":2893,"enrollment":2894,"conditions":4849,"interventions":4850},[89],[2896,2897,2898,2899,2900,2901,2902,2903,2904,2905,2906,2907,2908,2909,2910,2911,2912],[2870,2914,2845],{"nctId":2835,"briefTitle":2836,"status":448,"phases":4852,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":1431,"conditions":4853,"interventions":4854},[89],[2841],[2843,2844,2815,2845,2846,2847,2848,2849,2850,2851,2852,2853],{"trials":4856,"activeCount":100},[],{"trials":4858,"activeCount":100},[],{"trials":4860,"activeCount":100},[4861],{"nctId":4862,"briefTitle":4863,"status":463,"phases":4864,"primaryCompletion":4865,"completion":4865,"start":1858,"enrollment":554,"conditions":4866,"interventions":4867},"NCT02105116","AML Therapy With Irradiated Allogeneic Cells",[92],"2015-12-16",[2896,2897,2898,2899,2900,2901,2903,2904,2905,2906,2907,2908,2909,2910,2911,2912],[4868,2845,4869,4870],"fludarabine phosphate","donor lymphocytes","G-CSF",{"intervention":4821,"totalTrials":705,"cells":4872},{"EARLY_PHASE1":4873,"PHASE1":4875,"PHASE2":4877,"PHASE3":4879,"PHASE4":4881,"NA":4883},{"trials":4874,"activeCount":100},[],{"trials":4876,"activeCount":100},[],{"trials":4878,"activeCount":100},[],{"trials":4880,"activeCount":100},[],{"trials":4882,"activeCount":100},[],{"trials":4884,"activeCount":100},[4885,4889],{"nctId":4813,"briefTitle":4814,"status":448,"phases":4886,"primaryCompletion":4816,"completion":4816,"start":4817,"enrollment":1380,"conditions":4887,"interventions":4888},[],[4819],[2365,4821],{"nctId":4890,"briefTitle":4891,"status":448,"phases":4892,"primaryCompletion":4893,"completion":4893,"start":2165,"enrollment":4894,"conditions":4895,"interventions":4897},"NCT02550470","Evaluation of Micropore\"s SpiraLith Absorbents",[],"2016-10",186,[4896],"Airway Management During Operative Procedure",[4821],{"intervention":4211,"totalTrials":705,"cells":4899},{"EARLY_PHASE1":4900,"PHASE1":4902,"PHASE2":4908,"PHASE3":4910,"PHASE4":4912,"NA":4914},{"trials":4901,"activeCount":100},[],{"trials":4903,"activeCount":100},[4904],{"nctId":4202,"briefTitle":4203,"status":448,"phases":4905,"primaryCompletion":4205,"completion":4205,"start":4206,"enrollment":3569,"conditions":4906,"interventions":4907},[88],[4208],[4176,4210,4211],{"trials":4909,"activeCount":100},[],{"trials":4911,"activeCount":100},[],{"trials":4913,"activeCount":100},[],{"trials":4915,"activeCount":100},[4916],{"nctId":4917,"briefTitle":4918,"status":463,"phases":4919,"primaryCompletion":4920,"completion":4920,"start":4921,"enrollment":96,"conditions":4922,"interventions":4924},"NCT02289989","Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis",[92],"2017-01","2014-11",[4923],"Atopic Dermatitis",[4925,4211],"Oregano extract cream",{"intervention":3364,"totalTrials":705,"cells":4927},{"EARLY_PHASE1":4928,"PHASE1":4930,"PHASE2":4932,"PHASE3":4938,"PHASE4":4940,"NA":4942},{"trials":4929,"activeCount":100},[],{"trials":4931,"activeCount":100},[],{"trials":4933,"activeCount":100},[4934],{"nctId":3357,"briefTitle":3358,"status":448,"phases":4935,"primaryCompletion":3360,"completion":3360,"start":3361,"enrollment":913,"conditions":4936,"interventions":4937},[89],[2337],[3348,3364],{"trials":4939,"activeCount":100},[],{"trials":4941,"activeCount":100},[],{"trials":4943,"activeCount":100},[4944],{"nctId":4945,"briefTitle":4946,"status":448,"phases":4947,"primaryCompletion":4948,"completion":4949,"start":4950,"enrollment":467,"conditions":4951,"interventions":4955},"NCT03873337","Persistence Targeted Smoking Cessation in Serious Mental Illness (SMI)",[92],"2022-01-10","2022-01-31","2019-04-22",[4952,2337,4953,4632,2240,4954],"Tobacco Use","Tobacco Use Cessation","Schizoaffective Disorder",[3364],{"intervention":4957,"totalTrials":705,"cells":4958},"Cisplatin",{"EARLY_PHASE1":4959,"PHASE1":4961,"PHASE2":4963,"PHASE3":4977,"PHASE4":4979,"NA":4981},{"trials":4960,"activeCount":100},[],{"trials":4962,"activeCount":100},[],{"trials":4964,"activeCount":100},[4965],{"nctId":4966,"briefTitle":4967,"status":1968,"phases":4968,"primaryCompletion":4969,"completion":4969,"start":4970,"enrollment":16,"conditions":4971,"interventions":4976},"NCT04920344","Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy",[89],"2025-05-08","2021-07-19",[4972,4973,4974,4975],"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma",[4957],{"trials":4978,"activeCount":100},[],{"trials":4980,"activeCount":100},[],{"trials":4982,"activeCount":100},[4983],{"nctId":4984,"briefTitle":4985,"status":463,"phases":4986,"primaryCompletion":4987,"completion":4987,"start":4988,"enrollment":28,"conditions":4989,"interventions":5002},"NCT02177838","Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer",[92],"2019-08-22","2015-03-25",[4990,4991,4992,4993,4994,4995,4996,4997,4998,4999,5000,5001],"Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Verrucous Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Verrucous Carcinoma of the Larynx","Tongue Cancer",[5003,5004],"cetuximab","cisplatin",{"intervention":5003,"totalTrials":705,"cells":5006},{"EARLY_PHASE1":5007,"PHASE1":5009,"PHASE2":5011,"PHASE3":5013,"PHASE4":5015,"NA":5017},{"trials":5008,"activeCount":100},[],{"trials":5010,"activeCount":100},[],{"trials":5012,"activeCount":100},[],{"trials":5014,"activeCount":100},[],{"trials":5016,"activeCount":100},[],{"trials":5018,"activeCount":100},[5019,5029],{"nctId":5020,"briefTitle":5021,"status":448,"phases":5022,"primaryCompletion":5023,"completion":3567,"start":5024,"enrollment":16,"conditions":5025,"interventions":5028},"NCT02324608","Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer",[92],"2020-12-09","2015-01-30",[5026,5027],"Recurrent Skin Cancer","Squamous Cell Carcinoma of the Skin",[5003],{"nctId":4984,"briefTitle":4985,"status":463,"phases":5030,"primaryCompletion":4987,"completion":4987,"start":4988,"enrollment":28,"conditions":5031,"interventions":5032},[92],[4990,4991,4992,4993,4994,4995,4996,4997,4998,4999,5000,5001],[5003,5004],{"intervention":5034,"totalTrials":96,"cells":5035},"Institutional standard intravenous immune globulin treatment",{"EARLY_PHASE1":5036,"PHASE1":5038,"PHASE2":5040,"PHASE3":5042,"PHASE4":5044,"NA":5046},{"trials":5037,"activeCount":100},[],{"trials":5039,"activeCount":100},[],{"trials":5041,"activeCount":100},[],{"trials":5043,"activeCount":100},[],{"trials":5045,"activeCount":100},[],{"trials":5047,"activeCount":100},[5048],{"nctId":5049,"briefTitle":5050,"status":448,"phases":5051,"primaryCompletion":5052,"completion":5053,"start":5054,"enrollment":655,"conditions":5055,"interventions":5057},"NCT04818177","Immunoglobulin G Therapy Dose Optimization",[],"2025-07-01","2025-08-01","2021-04-01",[34,5056],"Immune Deficiency",[5034],{"intervention":5059,"totalTrials":96,"cells":5060},"Control",{"EARLY_PHASE1":5061,"PHASE1":5063,"PHASE2":5065,"PHASE3":5067,"PHASE4":5069,"NA":5071},{"trials":5062,"activeCount":100},[],{"trials":5064,"activeCount":100},[],{"trials":5066,"activeCount":100},[],{"trials":5068,"activeCount":100},[],{"trials":5070,"activeCount":100},[],{"trials":5072,"activeCount":100},[5073],{"nctId":5074,"briefTitle":5075,"status":1899,"phases":5076,"primaryCompletion":5077,"completion":5078,"start":5079,"enrollment":100,"conditions":5080,"interventions":5082},"NCT06469775","LiSWT for Men With Erectile Dysfunction",[92],"2029-09-01","2031-09-01","2025-03-01",[5081],"Erectile Dysfunction",[5059],{"intervention":5084,"totalTrials":96,"cells":5085},"romidepsin",{"EARLY_PHASE1":5086,"PHASE1":5088,"PHASE2":5090,"PHASE3":5092,"PHASE4":5094,"NA":5096},{"trials":5087,"activeCount":100},[],{"trials":5089,"activeCount":100},[],{"trials":5091,"activeCount":100},[],{"trials":5093,"activeCount":100},[],{"trials":5095,"activeCount":100},[],{"trials":5097,"activeCount":100},[5098],{"nctId":5099,"briefTitle":5100,"status":463,"phases":5101,"primaryCompletion":5102,"completion":5102,"start":4921,"enrollment":96,"conditions":5103,"interventions":5105},"NCT02203578","Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease",[92],"2016-06-14",[5104],"Graft Versus Host Disease",[5084],{"intervention":4925,"totalTrials":96,"cells":5107},{"EARLY_PHASE1":5108,"PHASE1":5110,"PHASE2":5112,"PHASE3":5114,"PHASE4":5116,"NA":5118},{"trials":5109,"activeCount":100},[],{"trials":5111,"activeCount":100},[],{"trials":5113,"activeCount":100},[],{"trials":5115,"activeCount":100},[],{"trials":5117,"activeCount":100},[],{"trials":5119,"activeCount":100},[5120],{"nctId":4917,"briefTitle":4918,"status":463,"phases":5121,"primaryCompletion":4920,"completion":4920,"start":4921,"enrollment":96,"conditions":5122,"interventions":5123},[92],[4923],[4925,4211],{"intervention":4830,"totalTrials":96,"cells":5125},{"EARLY_PHASE1":5126,"PHASE1":5128,"PHASE2":5130,"PHASE3":5132,"PHASE4":5134,"NA":5136},{"trials":5127,"activeCount":100},[],{"trials":5129,"activeCount":100},[],{"trials":5131,"activeCount":100},[],{"trials":5133,"activeCount":100},[],{"trials":5135,"activeCount":100},[],{"trials":5137,"activeCount":100},[5138],{"nctId":4823,"briefTitle":4824,"status":463,"phases":5139,"primaryCompletion":4826,"completion":2395,"start":4816,"enrollment":28,"conditions":5140,"interventions":5141},[92],[4828],[4830,2365],{"intervention":5143,"totalTrials":96,"cells":5144},"Inhibition of Sweet Taste by Ibuprofen Oral Rinses",{"EARLY_PHASE1":5145,"PHASE1":5147,"PHASE2":5149,"PHASE3":5151,"PHASE4":5153,"NA":5155},{"trials":5146,"activeCount":100},[],{"trials":5148,"activeCount":100},[],{"trials":5150,"activeCount":100},[],{"trials":5152,"activeCount":100},[],{"trials":5154,"activeCount":100},[],{"trials":5156,"activeCount":100},[5157],{"nctId":5158,"briefTitle":5159,"status":448,"phases":5160,"primaryCompletion":4670,"completion":3904,"start":5161,"enrollment":481,"conditions":5162,"interventions":5165},"NCT06291337","Ibuprofen Inhibits Human Sweet Taste",[92],"2020-06-01",[5163,5164],"Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Ibuprofen Solution in Healthy Participants","Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Naproxen Solution in Healthy Participants",[5143,5166],"Inhibition of Sweet Taste by Naproxen Oral Rinses",{"intervention":5166,"totalTrials":96,"cells":5168},{"EARLY_PHASE1":5169,"PHASE1":5171,"PHASE2":5173,"PHASE3":5175,"PHASE4":5177,"NA":5179},{"trials":5170,"activeCount":100},[],{"trials":5172,"activeCount":100},[],{"trials":5174,"activeCount":100},[],{"trials":5176,"activeCount":100},[],{"trials":5178,"activeCount":100},[],{"trials":5180,"activeCount":100},[5181],{"nctId":5158,"briefTitle":5159,"status":448,"phases":5182,"primaryCompletion":4670,"completion":3904,"start":5161,"enrollment":481,"conditions":5183,"interventions":5184},[92],[5163,5164],[5143,5166],{"intervention":5186,"totalTrials":96,"cells":5187},"Interferon-beta 1b",{"EARLY_PHASE1":5188,"PHASE1":5190,"PHASE2":5192,"PHASE3":5194,"PHASE4":5196,"NA":5198},{"trials":5189,"activeCount":100},[],{"trials":5191,"activeCount":100},[],{"trials":5193,"activeCount":100},[],{"trials":5195,"activeCount":100},[],{"trials":5197,"activeCount":100},[],{"trials":5199,"activeCount":100},[5200],{"nctId":5201,"briefTitle":5202,"status":448,"phases":5203,"primaryCompletion":5204,"completion":5204,"start":5205,"enrollment":4291,"conditions":5206,"interventions":5208},"NCT00468182","Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis",[],"2011-12","2007-04",[5207],"Multiple Sclerosis",[5186],{"intervention":5210,"totalTrials":96,"cells":5211},"COVID-19 Convalescent Plasma",{"EARLY_PHASE1":5212,"PHASE1":5214,"PHASE2":5216,"PHASE3":5218,"PHASE4":5220,"NA":5222},{"trials":5213,"activeCount":100},[],{"trials":5215,"activeCount":100},[],{"trials":5217,"activeCount":100},[],{"trials":5219,"activeCount":100},[],{"trials":5221,"activeCount":100},[],{"trials":5223,"activeCount":100},[5224],{"nctId":5225,"briefTitle":5226,"status":5227,"phases":5228,"conditions":5229,"interventions":5231},"NCT04420988","Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients","NO_LONGER_AVAILABLE",[],[3935,5230,2747],"SARS-CoV 2",[5210],{"intervention":5233,"totalTrials":96,"cells":5234},"Exparel",{"EARLY_PHASE1":5235,"PHASE1":5237,"PHASE2":5239,"PHASE3":5241,"PHASE4":5243,"NA":5245},{"trials":5236,"activeCount":100},[],{"trials":5238,"activeCount":100},[],{"trials":5240,"activeCount":100},[],{"trials":5242,"activeCount":100},[],{"trials":5244,"activeCount":100},[],{"trials":5246,"activeCount":100},[5247],{"nctId":5248,"briefTitle":5249,"status":448,"phases":5250,"primaryCompletion":5251,"completion":5251,"start":1858,"enrollment":2702,"conditions":5252,"interventions":5254},"NCT02072135","Exparel and Ankle Surgery",[92],"2015-11",[5253],"Ankle Fracture",[5233],{"intervention":4868,"totalTrials":96,"cells":5256},{"EARLY_PHASE1":5257,"PHASE1":5259,"PHASE2":5261,"PHASE3":5263,"PHASE4":5265,"NA":5267},{"trials":5258,"activeCount":100},[],{"trials":5260,"activeCount":100},[],{"trials":5262,"activeCount":100},[],{"trials":5264,"activeCount":100},[],{"trials":5266,"activeCount":100},[],{"trials":5268,"activeCount":100},[5269],{"nctId":4862,"briefTitle":4863,"status":463,"phases":5270,"primaryCompletion":4865,"completion":4865,"start":1858,"enrollment":554,"conditions":5271,"interventions":5272},[92],[2896,2897,2898,2899,2900,2901,2903,2904,2905,2906,2907,2908,2909,2910,2911,2912],[4868,2845,4869,4870],{"intervention":4869,"totalTrials":96,"cells":5274},{"EARLY_PHASE1":5275,"PHASE1":5277,"PHASE2":5279,"PHASE3":5281,"PHASE4":5283,"NA":5285},{"trials":5276,"activeCount":100},[],{"trials":5278,"activeCount":100},[],{"trials":5280,"activeCount":100},[],{"trials":5282,"activeCount":100},[],{"trials":5284,"activeCount":100},[],{"trials":5286,"activeCount":100},[5287],{"nctId":4862,"briefTitle":4863,"status":463,"phases":5288,"primaryCompletion":4865,"completion":4865,"start":1858,"enrollment":554,"conditions":5289,"interventions":5290},[92],[2896,2897,2898,2899,2900,2901,2903,2904,2905,2906,2907,2908,2909,2910,2911,2912],[4868,2845,4869,4870],{"intervention":4870,"totalTrials":96,"cells":5292},{"EARLY_PHASE1":5293,"PHASE1":5295,"PHASE2":5297,"PHASE3":5299,"PHASE4":5301,"NA":5303},{"trials":5294,"activeCount":100},[],{"trials":5296,"activeCount":100},[],{"trials":5298,"activeCount":100},[],{"trials":5300,"activeCount":100},[],{"trials":5302,"activeCount":100},[],{"trials":5304,"activeCount":100},[5305],{"nctId":4862,"briefTitle":4863,"status":463,"phases":5306,"primaryCompletion":4865,"completion":4865,"start":1858,"enrollment":554,"conditions":5307,"interventions":5308},[92],[2896,2897,2898,2899,2900,2901,2903,2904,2905,2906,2907,2908,2909,2910,2911,2912],[4868,2845,4869,4870],{"intervention":5310,"totalTrials":96,"cells":5311},"Varenicline",{"EARLY_PHASE1":5312,"PHASE1":5314,"PHASE2":5316,"PHASE3":5318,"PHASE4":5320,"NA":5322},{"trials":5313,"activeCount":100},[],{"trials":5315,"activeCount":100},[],{"trials":5317,"activeCount":100},[],{"trials":5319,"activeCount":100},[],{"trials":5321,"activeCount":100},[],{"trials":5323,"activeCount":100},[5324],{"nctId":5325,"briefTitle":5326,"status":448,"phases":5327,"primaryCompletion":1858,"completion":1858,"start":5328,"enrollment":5329,"conditions":5330,"interventions":5331},"NCT01308736","Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit",[92],"2011-01",73,[4632],[5310]]